

ISPOR 2018

May 19-23 2018 | Baltimore, MD, USA

www.ispor.org



Wednesday Research Poster Presentations

POSTER SESSION V: Poster Display Hours – 8:30 AM - 1:30 PM
Poster Author Discussion Hour – 12:30 PM - 1:30 PM

POSTER SESSION V

PMD: MEDICAL DEVICES/DIAGNOSTICS

PIN: INFECTION

PSY: SYSTEMIC DISORDERS/CONDITIONS

ROWS A-C

ROWS C-F

ROWS F-K

Research Poster Presentations – Session V

<u>Acceptance Code</u>	<u>Page #</u>	<u>Topic – Subtopic</u>
PMD1–PMD27	3-5	MEDICAL DEVICES/DIAGNOSTICS - Clinical Outcomes Studies
PMD28-PMD77	5-9	MEDICAL DEVICES/DIAGNOSTICS - Cost Studies
PMD78–PMD80	9	MEDICAL DEVICES/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies
PMD81–PMD122	9-12	MEDICAL DEVICES/DIAGNOSTICS - Health Care Use & Policy Studies
PIN1–PIN24	12-14	INFECTION - Clinical Outcomes Studies
PIN25–PIN50	14-16	INFECTION - Cost Studies
PIN51–PIN59	16-17	INFECTION - Patient-Reported Outcomes & Patient Preference Studies
PIN60- PIN83	17-19	INFECTION - Health Care Use & Policy Studies
PSY1-PSY31	19-21	SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies
PSY32-PSY61	21-23	SYSTEMIC DISORDERS/CONDITIONS - Cost Studies
PSY62-PSY79	23-25	SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient Preference Studies
PSY81-PSY132	25-29	SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies

RESEARCH POSTER PRESENTATIONS – SESSION V

HEALTH CARE TREATMENT STUDIES

MEDICAL DEVICES/DIAGNOSTICS - Clinical Outcomes Studies

- PMD1 A1 USE OF VASCULAR CLOSURE DEVICES IN THE HOSPITAL SETTING FOR PERCUTANEOUS CORONARY PROCEDURES AND GENDER DIFFERENCES OF THE MYNX® VASCULAR CLOSURE DEVICE: RESULTS FROM A HOSPITAL CLAIMS ANALYSIS**
Mallow P¹, Belk K², Craver CW², Almedhychy A³,¹Xavier University, Cincinnati, OH, USA, ²Vizient Inc., Mooresville, NC, USA, ³Cardinal Health, Milpitas, CA, USA
- PMD2 A2 THE BURDEN OF SICKLE CELL DISEASE**
Dierick K, Terumo BCT, Zaventem, Belgium
- PMD3 A3 A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF COMPLICATIONS POTENTIALLY ASSOCIATED WITH SINGLE INCISION SLINGS (SIS) FOR THE TREATMENT OF STRESS URINARY INCONTINENCE**
Lu X, Du D, Loyo-Berrios N, Cunkelman J, O'Neill A, Marinac-Dabic D, U.S. Food and Drug Administration, Silver Spring, MD, USA
- PMD4 A4 COST-EFFECTIVENESS ANALYSIS OF HIGH-SENSITIVITY TROPONIN T VERSUS CONVENTIONAL TROPONIN I TESTING FOR ACUTE MYOCARDIAL INFARCTION**
Hsu W¹, Galm B¹, Hsu S², Lee C³,¹Harvard University, Boston, MA, USA, ²Tunghai University, Taichung, Taiwan, ³National Taiwan University Hospital, Taipei, Taiwan
- PMD5 A5 EXPERIMENTAL STUDY ON THE CHANGES OF SPHINGOSINE 1-PHOSPHATE AND MATRIX METALLOPROTEINASES IN SERUM OF PATIENTS WITH OSTEOARTHRITIS**
Liu D¹, Yang H², Wang Z²,¹Xi'an NO.5 hospital, xi'an, China, ²Xi'an Jiaotong University Hospital, xi'an, China
- PMD6 A6 REAL-WORLD DATA ANALYSIS OF CONFIRMATORY BIOPSY UTILIZATION IN SUSPECTED PROSTATE CANCER PATIENTS**
Scott J, Concepcion R, Garofalo D, Verma-Kurvari S, Xu B, Montgomery J, Integra Connect, West Palm Beach, FL, USA
- PMD7 A7 BIOPSY PROCEDURES IN PATIENTS WITH PRIMARY LUNG CANCER**
Zhang Y¹, Lavin J², Liu E², Shi L¹,¹Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA, ²Intuitive Surgical, Sunnyvale, CA, USA
- PMD8 A8 SERUM AUTOANTIBODIES MULTI-TESTING IN RHEUMATOID ARTHRITIS IN PRIMARY CARE CAN REDUCE AVOIDABLE COSTS ASSOCIATED TO FALSE POSITIVES. A SIMULATION STUDY IN THE UNITED STATES OF AMERICA**
Mascialino B¹, Swiniarski S², Gehring I², Poorafshar M¹, Tarrant T³,¹Thermo Fisher Scientific, Uppsala, Sweden, ²Thermo Fisher Scientific, Freiburg, Germany, ³Duke School of Medicine, Durham, NC, USA
- PMD9 A9 THE CORRELATION STUDY BETWEEN COMPLEMENT C3 LEVEL AND COMMON CONNECTIVE TISSUE DISEASE ACTIVITY AND SECONDARY MULTI-ORGANIC INJURY**
Liu J, **Liu D**, Xi'an No.5 Hospital, Xi'an, China
- PMD10 A10 THE RELATIONSHIP BETWEEN COMPLIANCE AND BLINDNESS PREVENTION IN ECONOMIC MODELS FOR DIABETIC RETINOPATHY SCREENING**
Herring W, Gould IG, Zhang Y, Mladi DM, RTI Health Solutions, Research Triangle Park, NC, USA
- PMD11 A11 HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IS NOT “THE FEMALE ERECTILE DYSFUNCTION (ED)”’: CHALLENGES WITH THE CHARACTERIZATION OF HSDD IN WOMEN**
Kingsberg S¹, Al-Khateeb Z², Karkare S², Hadker N², Lim-Watson M³,¹University Hospitals Cleveland Medical Center, Cleveland, OH, USA, ²Trinity Partners, Waltham, MA, USA, ³AMAG Pharmaceuticals, Inc., Waltham, MA, USA
- PMD12 A12 A SIMPLE RISK PREDICTION MODEL FOR HIGH-RISK ADENOMATOUS POLYPS AT THE TIME OF COLONOSCOPY**
Boyne DJ¹, Lix L², Town S³, Heitman SJ³, Hilsden RJ³, Brenner DR³,¹University of Calgary, Calgary, ON, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³University of Calgary, Calgary, AB, Canada

- PMD13 A13 A CANADIAN COST-UTILITY ANALYSIS OF TWO TRABECULAR MICRO-BYPASS STENTS IN PATIENTS WITH MILD-TO-MODERATE OPEN-ANGLE GLAUCOMA**
 Ahmed II¹, Goeree R², Patel V³, Murray J⁴, **Falvey H**⁵, Podbielski DW¹,¹Prism Eye Institute, Mississauga, ON, Canada, ²Professor Emeritus, McMaster University and Goeree Consulting Ltd, Hamilton, ON, Canada, ³Pharmerit International, Bethesda, MD, USA, ⁴Glaukos Corp, Richmond Hill, ON, Canada, ⁵Glaukos Corp, San Clemente, CA, USA
- PMD14 A14 COMPARATIVE EFFECTIVENESS OF A BILAYERED LIVING CELLULAR CONSTRUCT AND AN ACELLULAR FETAL BOVINE COLLAGEN DRESSING IN THE TREATMENT OF VENOUS LEG ULCERS**
Sabolinski M, Sabolinski LLC., Franklin, MA, USA
- PMD15 A15 BENEFITS OF A HEART-SHAPED SUTURING TECHNIQUE IN CESAROTOMY CLOSURE: EXPERIENCE FROM AN ACADEMIC MEDICAL CENTER IN CHINA**
Wang Y¹, Shang M¹, Zhou Y¹, Li J¹, Wu Z¹, Li X¹, Ran J¹, Yang F², Feng W³, Xuan J⁴,¹The First Affiliated Hospital of Xiamen University, Xiamen, China, ²Shanghai Centennial Scientific Ltd, Shanghai, China, ³Institute of Pharmaceutical Economics, Sun Yat - sen University, Guangzhou, China, ⁴Sun Yat-sen University, Guangzhou, China
- PMD16 A16 ARE ALL ENDOSCOPIC SURGICAL STAPLERS THE SAME? FINDINGS FROM A REAL-WORLD ASSESSMENT IN BARIATRIC PROCEDURES**
 Roy S¹, Yadalam S², **Johnston SS**³,¹Ethicon Inc, Somerville, NJ, USA, ²Johnson & Johnson Co., New Brunswick, NJ, USA, ³Johnson & Johnson, Inc., New Brunswick, NJ, USA
- PMD17 A17 IMPACT OF V-GO VERSUS MULTIPLE DAILY INJECTIONS ON GLYCEMIC CONTROL, INSULIN UTILIZATION AND HEALTHCARE COSTS AMONG INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS**
Raval A¹, Nguyen M², Zhou S¹, Grabner M¹, Barron J¹, Quimbo R¹,¹HealthCore, Inc., Wilmington, DE, USA, ²Valeritas, Inc., Bridgewater, NJ, USA
- PMD18 A18 VASCULAR ACCESS OUTCOMES: IMPACT ON QUALITY OF LIFE AND ASSOCIATED COSTS FOLLOWING SURGICAL OR ENDOVASCULAR ARTERIOVENOUS FISTULA CREATION FOR HEMODIALYSIS PATIENTS**
Yu TM, Tang J, Tradonsky AN, Arnold RJ, Navigant Consulting, Inc., San Francisco, CA, USA
- PMD19 A19 PROVISIONAL VERSUS COMPLEX OR TRYTON STENTING STRATEGIES FOR SIGNIFICANT BIFURCATED LESIONS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SYSTEMATIC REVIEW**
Parsley L, Brandt DM, Carr DL, Alexander ES, Mallow P, Xavier University, Cincinnati, OH, USA
- PMD20 A20 A SYSTEMATIC REVIEW OF CLINICAL EFFICACY ASSOCIATED WITH USE OF PROTEASE-MODULATING INTERVENTIONS WITH DIABETIC FOOT ULCER OR VENOUS LEG ULCER**
 Yeowell G, **Betts A**, Odeyemi I, Fatoye F, Manchester Metropolitan University, Manchester, UK
- PMD21 A21 HOSPITAL RELATED CLINICAL AND ECONOMICAL OUTCOMES OF A BICRUCIATE KNEE SYSTEM IN TOTAL KNEE ARTHROPLASTY PATIENTS**
 Mayman DJ¹, **Patel AR**², Carroll KM¹,¹Hospital for Special Surgery, New York, NY, USA, ²Smith & Nephew Inc, Fort-worth, TX, USA
- PMD22 A22 COMPARISON OF ECONOMIC AND CLINICAL OUTCOMES BETWEEN SKIN STAPLES PLUS WOUND DRESSINGS AND 2-OCTYL CYANOACRYLATE PLUS POLYMER MESH TAPE AMONG PATIENTS UNDERGOING CESAREAN SECTION**
Johnston SS¹, Geethu R², Costa M², Lee SH³, Schmitz N⁴, Chen BP⁵,¹Johnson & Johnson, Inc., New Brunswick, NJ, USA, ²Johnson & Johnson, North Sydney NSW, Australia, ³Johnson & Johnson Medical, Asia Pacific, Singapore, Singapore, ⁴Ethicon, Johnson & Johnson, Somerville, NJ, USA, ⁵Ethicon Inc, Somerville, NJ, USA
- PMD23 A23 COMPARATIVE ANALYSIS INVESTIGATING THE IMPACT OF IMPLANT DESIGN ON HOSPITAL LENGTH OF STAY AND DISCHARGE DESTINATION IN A DUTCH HOSPITAL WITH AN ESTABLISHED ENHANCED RECOVERY PROGRAM**
 Meermans G¹, Galvain T², Wigham R³, Do Rego B⁴, **Schroer D**⁵,¹Bravis Hospital, Bergen op Zoom, The Netherlands, ²Johnson & Johnson Medical SAS, Issy les Moulineaux, France, ³Johnson & Johnson Medical Limited, Livingston, West Lothian, UK, ⁴DePuy Synthes, Leeds, West Yorkshire, UK, ⁵Johnson & Johnson Medical, Amersfoort, The Netherlands
- PMD24 A24 EFFICACY AND SAFETY OF INSULIN PUMPS FOR THE SECOND LINE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES**

Marra L¹, Oliveira GL¹, Brito AF²,¹NATIONAL COMMISSION FOR INCORPORATION OF TECHNOLOGIES IN SUS, Brazil, Brasilia, Brazil, ²Brazilian Ministry of Health, Brasilia, Brazil

PMD25 A25 A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS OF SCREENING FOR HEPATOCELLULAR CARCINOMA

Chawla AS¹, Kohli RK²,¹Theralnsight Pvt. Ltd., Bangalore, India, ²Punjabi University, Patiala, India

PMD26 A26 IMPROVED QUALITY CONTROL WITH SUBCUTANEOUS (SC) INFUSION PUMP

Lukács M¹, Oláh A¹, Boncz I¹, Csikós Á¹, Busa C¹, Frank N¹, **Endrei D**¹, Pakai A²,¹University of Pécs, Pécs, Hungary, ²University of Pécs, Zalaegerszeg, Hungary

PMD27 A27 EFFICIENCY OF THE USE OF LONG-ACTING REVERSIBLE CONTRACEPTION: A SYSTEMATIC REVIEW OF THE LITERATURE

Gomez de la Rosa F¹, Alvis Zakzuk J², Alvis Guzman N³, Moreno DJ⁴, Rincon M⁵, Vargas JC⁶, Edna Estrada F⁷, Urrego M⁸, Rubio ML⁹, Alvarez Mesa C⁸, Tolosa J⁵,¹ALZAK Foundation, Cartagena, Colombia, ²ALZAK Foundation, Centro de investigación Seguridad Materna - Grupo de investigación para la salud materna, perinatal y de la mujer - Clínica Maternidad Rafael Calvo, CARTAGENA, Colombia, ³Universidad de Cartagena - ALZAK Foundation, Cartagena, Colombia, ⁴Ministerio de Salud y protección Colombia, Bogota, Colombia, ⁵Oregon Health & Science University, Portland, OR, USA, ⁶Profamilia Colombia, Bogota, Colombia, ⁷Centro de Investigación para la Salud Materna Perinatal y de la Mujer. Clínica Maternidad Rafael Calvo C., Cartagena de Indias, Colombia, ⁸Universidad de Antioquia, Medellín, Colombia, ⁹UNFPA, Bogota, Colombia

MEDICAL DEVICES/DIAGNOSTICS - Cost Studies

PMD28 A28 BUDGET IMPACT ANALYSIS OF THE ADVANCE LUBRICATH® FOLEY CATHETER TRAY® FOR URINARY CATHETERIZATION OF LONG DURATION IN MEXICO

Ruiz Miranda C¹, Rodriguez Mendoza MM², Gomez Zamesa M¹, Sanchez Trejo K²,¹Becton Dickinson, Mexico City, Mexico, ²Consultoría en Investigación Farmacéutica, Mexico State, Mexico

PMD29 A29 BUDGET IMPACT ANALYSIS (BIA) OF POINT-OF-CARE OF HBA1C MONITORING IN BELGIAN, GERMAN AND SWISS PATIENTS WITH DIABETES MELLITUS TYPE II

Navarro F¹, Hren R², Boltyenkov A³,¹Siemens Healthcare Diagnostics Inc., Norwood, MA, USA, ²Siemens Healthcare Diagnostics GmbH, Vienna, Austria, ³Siemens Healthcare GmbH, Erlangen, Germany

PMD30 A30 ECONOMIC ANALYSIS OF D-DIMER TEST USED FOR THE DIAGNOSIS OF VENOUS THROMBOEMBOLISM IN COLOMBIA

Galvez K¹, Robles A², Tamayo C³, Simbaqueba E⁴,¹Hospital Pablo Tobón Uribe, Medellin, Colombia, ²Universidad de Alicante, Alicante, Spain, ³U Nacional, Bogota, Colombia, ⁴Werfen, Bogota, Colombia

PMD31 A31 BUDGET IMPACT ANALYSIS OF IMPLEMENTING 5MM DUAL-ENDED SAFETY PEN NEEDLES FOR INSULIN INJECTIONS IN US HOSPITALS

Ermakova A, Taylor S, Becton Dickinson, Franklin Lakes, NJ, USA

PMD32 A32 HEALTH ECONOMIC MODEL FOR ESTIMATING THE DIRECT COST IMPACT OF ADOPTING A VASCULAR ACCESS ANTIMICROBIAL BUNDLE OF SOLUTIONS IN ICU SETTINGS IN GERMANY

Palka-Santini M¹, **Topachevskiy O**²,¹3M Deutschland GmbH, Neuss, Germany, ²Digital Health Outcomes, Brussels, Belgium

PMD33 A33 BUDGET IMPACT ANALYSIS OF A NOVEL ALTERNATING PRESSURE SUPPORT SURFACE IN THE ACUTE CARE SETTING

Hayashi DE¹, Kill T², Fitzpatrick MA², Gutzwiller L², Dzioba DA², Peyerl FW¹,¹Boston Strategic Partners, Inc., Boston, MA, USA, ²Dabir Surfaces Inc., Harwood Heights, IL, USA

PMD34 A34 ARE SINGLE-PATIENT USE ELECTROCARDIOGRAPH CABLE AND LEAD SYSTEMS DURING CORONARY ARTERY BYPASS GRAFT MONITORING A BENEFIT TO HEALTHCARE PAYERS: A BUDGET IMPACT ANALYSIS

Saunders R¹, Lankiewicz J²,¹Coreva Scientific, Freiburg im Breisgau, Germany, ²Cardinal Health, Mansfield, MA, USA

PMD35 A35 STEROID-ELUTING SINUS IMPLANT VERSUS REVISION SURGERY FOR PATIENTS WITH RECURRENT CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): AN ECONOMIC EVALUATION MODEL

Ernst FR¹, Imhoff R¹, Minshall M¹, DeConde AS², Manes RP³,¹CTI Clinical Trial and Consulting Services, Covington, KY, USA, ²University of California - San Diego, San Diego, CA, USA, ³Yale School of Medicine, New Haven, CT, USA

- PMD36 A36 IMPACT OF DISTAL RADIUS STERILE KIT ON PROVIDER BUDGET IN THE USA**
Menzie AM¹, Vanderkarr M¹, Badin MS², Bhattacharyya S¹,¹DePuy Synthes, Inc., Raynham, MA, USA, ²Johnson and Johnson Medical Devices, Markham, ON, Canada
- PMD38 A37 IMPLANTABLE CARDIAC MONITOR COMPARED WITH CONVENTIONAL DIAGNOSTIC FOR UNEXPLAINED SYNCOPE: A COMBINED COST-EFFECTIVENESS AND BUDGET-IMPACT ANALYSIS**
Lucchetta RC¹, Riveros BS¹, Rosim MP², Holanda P³, Melo M³, Okumura LM³, Gonçalves VF⁴, Nita ME³,¹Federal University of Parana, Curitiba, Brazil, ²University of Sao Paulo, São Paulo, Brazil, ³MAPE Solutions, São Paulo, Brazil, ⁴BIOTRONIK Comercial Médica Ltda., Sao Paulo, Brazil
- PMD39 A38 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF VISCOSUPPLEMENTATION WITH SYNVIC FOR KNEE AND HIP OSTEOARTHRITIS**
Migliore A¹, Integlia D², Pompilio G², Di Giuseppe F², Aru C², Brown T³,¹"Ospedale S. Pietro FBF", Rome, Italy, ²ISHEO Srl, Rome, Italy, ³University of Cambridge, Cambridge, UK
- PMD40 A39 HEALTH TECHNOLOGY ASSESSMENT OF INVASIVE HOME MECHANICAL VENTILATION UNDER THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)**
Carvalhoes SR¹, Rodrigues DL¹, Cifuentes T¹, Borges M², Souza NC¹, Pinho AP¹, Guimarães T², Nogueira E³,¹HOSPITAL ALEMÃO OSWALDO CRUZ, SAO PAULO, Brazil, ²MINISTRY OF HEALTH, SAO PAULO, Brazil, ³Qmed Consulting, Køge, Denmark
- PMD41 A40 ECONOMIC IMPACT OF THE USE OF RAPID DEPLOYMENT VALVE REPLACEMENTS IN BRAZIL AND COLOMBIA**
Ferreira CN¹, **Mendoza CF**²,¹Edwards Lifesciences Latam, São Paulo, Brazil, ²Edwards Lifesciences Latam, Mexico City, Mexico
- PMD42 A41 A LITERATURE REVIEW OF TRANSRADIAL VS. TRANSFEMORAL LOWER EXTREMITY PERIPHERAL ARTERY INTERVENTIONS**
Iqyarto Z, Breitenfeldt M, Martinsen BJ, Cardiovascular Systems, Inc., St. Paul, MN, USA
- PMD43 A42 LATEST INSIGHTS ON THE COST EFFICIENCY OF THERAPEUTIC PLASMA EXCHANGE IN TREATING GUILLAIN-BARRE SYNDROME**
Dierick K, Terumo BCT, Zaventem, Belgium
- PMD44 A43 COMPARATIVE COSTS OF DENSE BREAST CANCER SCREENING AND RECALL: TOMOSYNTHESIS VS. ULTRASOUND**
Miller JD¹, Bonafede MM¹, Pohlman SK², Troeger KA²,¹Truven Health Analytics, an IBM Company, Cambridge, MA, USA, ²Hologic, Inc., Marlborough, MA, USA
- PMD45 A44 HEALTHCARE COST ASSOCIATED WITH CARDIAC IMPLANTABLE ELECTRONIC DEVICE INFECTIONS: USING A NATIONAL HEALTH INSURANCE CLAIMS DATABASE**
PARK H, Lee S, Jeong J, Medtronic Korea, Seoul, Korea, Republic of (South)
- PMD47 A45 ULTRAFILTRATION VS. DIURETICS FOR THE TREATMENT OF FLUID OVERLOAD IN HEART FAILURE PATIENTS: A HOSPITAL COST ANALYSIS**
Costanzo MR¹, Fonarow GC², **Rizzo JA**³,¹Advocate Health Care, Naperville, IL, USA, ²University of California Los Angeles, Los Angeles, CA, USA, ³Stony Brook University, Stony Brook, NC, USA
- PMD48 A46 DISPOSABLE VS. FIBER OPTIC REUSABLE BRONCHOSCOPES FOR HIGH-RISK PROCEDURES: COST-EFFECTIVENESS ANALYSIS (CEA)**
Yassin MH, Smith K, Univ of Pittsburgh, Pittsburgh, PA, USA
- PMD49 A47 COST EFFECTIVENESS OF ULTRA-VIOLET GERMICIDAL IRRADIATION IN CANADIAN HEALTH REGION**
Hall W, University of British Columbia, Vancouver, BC, Canada
- PMD50 A48 AN APPRAISAL OF THE QUALITY OF ECONOMIC EVIDENCE IN COST-EFFECTIVENESS AND COST-UTILITY STUDIES IDENTIFIED VIA SYSTEMATIC REVIEW FOR B-TYPE NATRIURETIC PEPTIDE-GUIDED THERAPY IN HEART FAILURE MANAGEMENT PATIENTS**
Marupuru S¹, Malone DC²,¹university of arizona, tucson, AZ, USA, ²University of Arizona, Tucson, AZ, USA
- PMD51 A49 COST-EFFECTIVENESS ANALYSIS OF BRONCHIAL THERMOPLASTY VERSUS PHARMACOLOGICAL THERAPIES IN PATIENTS WITH SEVERE ASTHMA IN MEXICO, COLOMBIA AND SPAIN**
Figuerola-Lara A¹, Aguirre-Perez T², Tapetado-Rodriguez F³, Puente-Maestu L⁴, Fernando-Cifuentes L⁵, Cañas-Arboleda A⁶, Cangelosi MJ⁷,¹Boston Scientific Mexico, Mexico City, Mexico, ²Instituto Mexicano de

Enfermedades Respiratorias, Mexico City, Mexico, ³Boston Scientific Ibérica, Madrid, Spain, ⁴Hospital Gregorio Marañón, Madrid, Spain, ⁵Boston Scientific Colombia, Bogota, Colombia, ⁶Pontificia Universidad Javeriana, Bogota, Colombia, ⁷Boston Scientific Corporation, Marlborough, MA, USA

- PMD53 A50 COST-EFFECTIVENESS AND RETURN ON INVESTMENT OF CONTINUOUS LATERAL ROTATION THERAPY TO PREVENT VENTILATOR-ASSOCIATED PNEUMONIA AND PRESSURE INJURIES IN THE CRITICAL CARE SETTING**
Kang SY, DiStefano MJ, Yehia F, Padula WV, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- PMD54 B1 COST - EFFECTIVENESS ANALYSIS OF ULTRASOUND SCREENING FOR THYROID CANCER IN ASYMPTOMATIC POPULATION**
Yang H¹, Li S², Guo JJ³, **Hu M**¹, ¹Sichuan University, Chengdu, China, ²West China Hospital, Sichuan University, Chengdu, China, ³University of Cincinnati, Cincinnati, OH, USA
- PMD55 B2 INSULIN DELIVERY SYSTEMS FOR TYPE 1 DIABETES MELLITUS - A COMPARISON USING A DECISION ANALYSIS MODELING APPROACH**
Rai P¹, Zhang Y¹, Stover A², Iloabuchi C¹, Kamal KM³, Chiumente M⁴, ¹West Virginia University, School of Pharmacy, Morgantown, WV, USA, ²West Virginia University, School of Pharmacy, Morgantown, WV, USA, ³Duquesne University School of Pharmacy, Pittsburgh, PA, USA, ⁴Italian Society for Clinical Pharmacy and Therapeutics, Milano, Italy
- PMD56 B3 COST-EFFECTIVENESS ANALYSIS OF THE USE OF COBLATION TECHNOLOGY VERSUS MECHANICAL DEBRIDEMENT IN KNEE CHONDROPLASTY - A UK NATIONAL HEALTH SERVICE PERSPECTIVE.**
Adeyemi A¹, Nherera L², Trueman P², ¹Smith & Nephew, Andover, MA, USA, ²Smith & Nephew, Hull, UK
- PMD57 B4 COST-EFFECTIVENESS ANALYSIS OF TRANSCATHETER AORTIC VALVE REPLACEMENT IN INOPERABLE PATIENTS WITH SEVERE AORTIC STENOSIS IN MEXICO**
Ferreira CN¹, **Mendoza CF**², Goodall G³, ¹Edwards Lifesciences Latam, São Paulo, Brazil, ²Edwards Lifesciences Latam, Mexico City, Mexico, ³Edwards Lifesciences, Nyon, Switzerland
- PMD58 B5 COST - EFFECTIVENESS OF THE USE OF THE INSULIN PUMP THERAPY VERSUS DAILY MULTIPLE INJECTIONS IN PATIENTS WITH TYPE 1 DIABETES AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY**
Roze S¹, **Doubova SV**², Gasca R³, Ferreira A², Barsoe C⁴, Valencia JE⁵, Baran J⁶, ¹HEVA HEOR Sarl, Lyon, France, ²Mexican Institute of Social Security, Mexico, Mexico, ³Medtronic Latin America, Mexico, Mexico, ⁴Medtronic Global, Northridge, CA, USA, ⁵Medtronic Latin America, Miami, FL, USA, ⁶Medtronic Mexico, Mexico, Mexico
- PMD59 B6 COST-EFFECTIVENESS OF SERIAL CERVICAL LENGTH SCREENING TO PREVENT PRETERM BIRTH AMONG HIGH-RISK U.S. WOMEN: A DECISION ANALYSIS**
Smart M¹, Seligman NS², Prioli KM¹, Gray LM², Pizzi LT¹, ¹Rutgers University, Piscataway, NJ, USA, ²University of Rochester Medical Center, Rochester, NY, USA
- PMD60 B7 MODELING THE IMPACT ON CLINICAL UTILITY, PATIENT HARMS, AND COST OF BIOMARKERS FOR THE MANAGEMENT OF INCIDENTALLY DETECTED PULMONARY NODULES**
Soneji SS¹, Silvestri GA², Tanner NT², Piscitello A³, Rinde H⁴, ¹Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USA, ²Medical University of South Carolina, Charleston, SC, USA, ³EmpiriQA, Long Grove, IL, USA, ⁴BioBridge Strategies, San Diego, CA, USA
- PMD61 B8 ECONOMIC EVALUATION OF THE NERVE CONDUCTION MEASURING DEVICE FOR THE DIAGNOSIS OF PERIPHERAL DIABETIC NEUROPATHY**
Soto Molina H¹, Diaz-Alvarez O¹, Sandoval-Avila M¹, Dominguez V¹, Sinta Cortes G¹, Rodriguez-Mendoza MM², ¹HS Estudios Farmacoeconómicos S.A. de C.V., Mexico City, Mexico, ²Independet consultant, Mexico, Mexico
- PMD62 B9 COST-EFFECTIVENESS OF BREAST CANCER SCREENING PROGRAM IN THE REPUBLIC OF KAZAKHSTAN**
Salikhanov I, Crape BL, Howie P, Nazarbayev University, Astana, Kazakhstan
- PMD63 B10 THE COST-EFFECTIVENESS ANALYSIS OF USING CHROMOAGAR FOR ACTIVE SURVEILLANCE OF CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII TO DETERMINE THE DURATION OF CONTACT ISOLATION IN INTENSIVE-CARE UNIT**
Chen T¹, Lin S², Shih N¹, ¹Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan, ²Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

- PMD64 B11 ECONOMIC EVALUATION OF THE ADVANCE LUBRICATH® FOLEY CATHETER TRAY® FOR URINARY CATHETERIZATION OF LONG DURATION**
Ruiz Miranda CI¹, Rodriguez Mendoza MM², Gomez Zamesa M¹, Sanchez Trejo K²,¹Becton Dickinson, Mexico City, Mexico, ²Consultoría en Investigación Farmacéutica, Mexico State, Mexico
- PMD65 B12 COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION WITH THE NEW REPOSITIONABLE SELF-EXPANDABLE EVOLUT R VERSUS COREVALVE SYSTEM IN INOPERABLE PATIENTS WITH SEVERE AORTIC STENOSIS IN MEXICO**
 Guitierrez M¹, Muñoz P¹, Lemus F¹, Flores B¹, Gryzbowski E², Valencia J³,¹Pharmamangement EAS S de RL de CV, Ciudad de México, Mexico, ²Medtronic, Ciudad de México, Mexico, ³Medtronic, Miami, FL, USA
- PMD66 B13 ADOPTING A PRAGMATIC METHODOLOGY TO EVALUATE COST-EFFECTIVENESS OF A SIMPLE INSULIN INFUSION DEVICE COMPARED WITH MULTIPLE DAILY INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES ON INSULIN**
Wahlqvist P¹, Warner J², Morlock R³,¹CeQur (Wales) Ltd, Cardiff, UK, ²CeQur Corporation, Marlborough, MA, USA, ³YourCareChoice, Ann Arbor, MI, USA
- PMD67 B14 ECONOMIC EVALUATION OF THE CONFIRMATORY ANTIBODY ASSAY AGAINST HIV-1 AND HIV-2 (GEENIUS™ HIV 1/2 SUPPLEMENTAL ASSAY) AS CONFIRMATORY AND DIFFERENTIATION HIV TEST.**
Soto Molina H, Diaz-Alvarez O, Sandoval-Avila M, HS Estudios Farmacoeconómicos S.A. de C.V., Mexico City, Mexico
- PMD68 B15 THE COST-EFFECTIVENESS OF A PUBLIC HEALTH NURSE PROGRAM TO SCREEN FOR AMBLYOPIA IN ONTARIO**
Asare AO¹, Masucci L¹, Penner M²,¹University of Toronto, Toronto, ON, Canada, ²Holland Bloorview Kids Rehabilitation Hospital, University of Toronto, East York, ON, Canada
- PMD69 B16 COST-EFFECTIVENESS OF A TWIN INTERLOCKING DEROTATION AND COMPRESSION SCREW CEPHALOMEDULLARY NAIL (2-SCREW NAIL)* WITH A SINGLE SCREW DEROTATION CEPHALOMEDULLARY NAIL (SINGLE-SCREW NAIL)** IN PATIENTS WITH INTERTROCHANTERIC HIP FRACTURES**
Nherera L, Trueman P, Horner A, Smith & Nephew, Hull, UK
- PMD70 B17 CERVICAL CANCER SCREENING DECISION MODEL**
Vaffis S, University of Arizona, Tucson, AZ, USA
- PMD71 B18 HEART RATE VARIABILITY TESTING: COULD IT CHANGE SPENDING FOR RHEUMATOID ARTHRITIS PATIENTS IN THE UNITED STATES? AN EXPLORATORY ECONOMIC ANALYSIS.**
Zimmermann M¹, Vodicka E¹, Holman A², Garrison LP¹,¹Consultants in Global Health, Seattle, WA, USA, ²Inmedix, Seattle, WA, USA
- PMD72 B19 COMPARING THE COSTS AND OUTCOMES OF A TWIN INTERLOCKING DEROTATION AND COMPRESSION SCREW CEPHALOMEDULLARY NAIL (2-SCREW NAIL)* WITH A SINGLE SCREW CEPHALOMEDULLARY NAIL (SINGLE-SCREW NAIL) IN PATIENTS WITH INTERTROCHANTERIC HIP FRACTURES**
Nherera L, Trueman P, Horner A, Smith & Nephew, Hull, UK
- PMD73 B20 COST-UTILITY ANALYSIS OF ISTENT TRABECULAR MICRO-BYPASS STENT VERSUS MEDICATIONS ONLY FOR PATIENTS WITH OPEN-ANGLE GLAUCOMA IN COLOMBIA**
Ordoñez JE, Ordoñez A, Osorio UM, True Consulting, Envigado, Colombia
- PMD74 B21 COST-UTILITY ANALYSIS OF TRABECULAR MICRO-BYPASS STENTS VERSUS LASER TRABECULOPLASTY FOR PATIENTS WITH OPEN-ANGLE GLAUCOMA IN COLOMBIA**
Ordoñez JE, Ordoñez A, Osorio UM, True Consulting, Envigado, Colombia
- PMD75 B22 COST-UTILITY ANALYSIS OF TWO ULTRASOUND-GUIDED BREAST BIOPSIES: VACUUM-ASSISTED BIOPSY VERSUS CONVENTIONAL CORE NEEDLE BIOPSY**
Zhou L¹, Liang Y², Li P², Ye L¹,¹Fudan University, Shanghai, China, ²Devicor Medical Device (Shanghai) Co., Ltd, Shanghai, China
- PMD76 B23 ACUTE HEALTHCARE UTILIZATION PATTERNS AMONG PEOPLE WITH TYPE 2 DIABETES USING PROFESSIONAL CGM IN THE UNITED STATES.**
Sierra JA, Shah M, Vigersky R, Kaufman FR, Flores Z, Gill MS, Stoltenberg LS, Medtronic Diabetes, Northridge, CA, USA

PMD77 B24 ULTRASOUND: A FAST LOW-COST TOOL FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS IN A SPECIALIZED CENTER

Santos-Moreno P¹, Buitrago-Garcia D², Villarreal L³, Alvis-Zakzuk N⁴, Carrasquilla M⁴, **Alvis Guzman N⁵**,¹Biomab, bogota, Colombia, ²SIIES investigation and research, Colombia, bogota, Colombia, ³Biomab, center for rheumatoid arthritis, bogota, Colombia, ⁴Alzak Foundation, Cartagena, Colombia, ⁵ALZAK Foundation- Universidad De La Costa, Barranquilla, Colombia

MEDICAL DEVICES/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies

PMD78 B25 USING TIME TRADE-OFF (TTO) SURVEYS TO MEASURE HEALTH UTILITIES ASSOCIATED WITH DIFFERENT URINARY CATHETER INNOVATIONS

Igawa Y¹, Krassioukov A², Averbeck MA³, Madersbacher H⁴, **Lloyd A⁵**, Sørensen J⁶, Bøgelund M⁷, Thiruchelvam N⁸,¹The University of Tokyo, Tokyo, Denmark, ²University of British Columbia, Vancouver, Denmark, ³Moinhos de Vento Hospital, Porto Alegre, Brazil, ⁴Medical University Innsbruck, Innsbruck, Austria, ⁵Acaster Lloyd Consulting Ltd., London, UK, ⁶Coloplast A/S, Humlebæk, Denmark, ⁷Incentive, Holte, Denmark, ⁸Cambridge University Hospitals NHS Trust, Cambridge, UK

PMD79 B26 THAI ADULTS' PREFERENCES AND WILLINGNESS-TO-PAY FOR COLORECTAL CANCER SCREENING: A DISCRETE CHOICE EXPERIMENT

Phisalprapa P¹, Chaiyakunapruk N², Ngorsuraches S³, Supakankunti S¹,¹Faculty of Economics, Chulalongkorn University, Bangkok, Thailand, ²Naresuan University, Phitsanulok, Thailand, ³South Dakota State University, Brookings, SD, USA

PMD80 B27 PATIENT AND CLINICIAN SATISFACTION WITH PHARMACOLOGICAL STRESS AGENTS (PSAS) USED IN SINGLE PHOTON EMISSION COMPUTERIZED TOMOGRAPHY MYOCARDIAL PERFUSION IMAGING (SPECT-MPI)

Shields AL¹, Hudgens S², Spalding J³, Kitt TM³, Ojo O¹, Kristy RM⁴, Mathias A¹, Morrissey L¹, Litcher-Kelly L¹, Houle CR³,¹Adelphi Values, Boston, MA, USA, ²Clinical Outcomes Solutions, Tucson, AZ, USA, ³Astellas Pharma Global Development, Inc., Northbrook, IL, USA, ⁴Astellas Pharma Global Development, Northbrook, IL, USA

MEDICAL DEVICES/DIAGNOSTICS - Health Care Use & Policy Studies

PMD81 B28 A DIGITAL HEALTH PLATFORM TO CREATE PERSONALIZED CARE EXPERIENCES FOR PATIENTS WITH CHRONIC DISEASE

Schultz A¹, Mehta J², Mehta S²,¹Partners Healthcare, Brookline, MA, USA, ²KEVA Health, Lexington, MA, USA

PMD82 B29 DETERMINANTS AND PATHWAYS OF REHABILITATION AFTER SURGICAL AORTIC VALVE REPLACEMENT: A POPULATION-BASED, RETROSPECTIVE STUDY WITH ADMINISTRATIVE DATA

Callea G, Borsoi L, Tarricone R, SDA Bocconi School of Management, Milan, Italy

PMD83 B30 ABLATION PROCEDURE USING NEWER RADIOFREQUENCY CATHETERS (THERMOCOOL® SF CATHETER OR THERMOCOOL SMARTTOUCH® CATHETER) VERSUS EARLIER GENERATION THERMOCOOL® CATHETER: A REAL-WORLD COMPARISON OF OUTCOMES USING A US HOSPITAL DATABASE

Goldstein LJ¹, Barnow A², Daskiran M³, Kalsekar I⁴, **Khanna R⁴**,¹Johnson & Johnson, Markham, ON, Canada, ²Johnson & Johnson, Diamond Bar, CA, USA, ³Janssen, New Brunswick, NJ, USA, ⁴Johnson & Johnson Co., New Brunswick, NJ, USA

PMD84 B31 SYSTEMATIC REVIEW OF ENDOBRONCHIAL ULTRASONOGRAPHY WITH GUIDE SHEATH

Kim S¹, Jo S¹, Lee K¹, Ko R¹, Kim S¹, Kim J²,¹National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South), ²Chung-Ang University Hospital, Seoul, Korea, Republic of (South)

PMD85 B32 ABLATION VERSUS ANTIARRHYTHMIC DRUG TREATMENT AMONG PATIENTS WITH ATRIAL FIBRILLATION: A PROPENSITY-MATCHED ANALYSIS

Jarman JW¹, March J², Goldstein LJ³, Liao R⁴, Kalsekar I⁵, Khanna R⁵, **Chitnis A⁶**,¹Royal Brompton Hospital, London, UK, ²Johnson & Johnson Medical Devices Companies, Irvine, CA, USA, ³Johnson & Johnson, Markham, ON, Canada, ⁴Janssen R&D US, Raritan, NJ, USA, ⁵Johnson & Johnson Co., New Brunswick, NJ, USA, ⁶Johnson & Johnson, New Brunswick, NJ, USA

PMD86 B33 EVALUATION OF CURRENT AND FUTURE PD-(L)1 TESTING REQUIREMENTS IN THE US

Katkhuda R, Carroll ER, Nash C, Carlow D, GfK, New York, NY, USA

PMD87 B34 UNDERSTANDING ECONOMIC MODELS IN MEDICAL DEVICES: AN ORGANIZATION'S PERSPECTIVE

Basu R, Chien H, Alsumali A, Medtronic, Mansfield, MA, USA

- PMD88 B35 COVERAGE AND REVIEWS OF MEDICAL DEVICES, GENOMIC AND DIAGNOSTIC TESTING BY US HEALTH PLANS**
Brook RA¹, Carlisle JA², Smeeding JE³,¹The JeSTARx Group & TPG-NPRT, Newfoundland, NJ, USA, ²The TPG-NPRT, Glastonbury, CT, USA, ³The TPG-NPRT & JeSTARx, Glastonbury, CT, USA
- PMD89 B36 FACTORS AFFECTING THE MEDICAL EQUIPMENT MAINTENANCE MANAGEMENT AT THE HOSPITAL: A SYSTEMATIC REVIEW**
Imani A¹, Doshmangir L², Bahreini R¹,¹Tabriz university of medical sciences, Tabriz, Iran (Islamic Republic of), ²Iranian Center of Excellence in Health Management, School of management and medical informatics, Tabriz University of Medical Sciences, Tabriz, Iran, Tabriz, Iran (Islamic Republic of)
- PMD90 B37 A SYSTEMATIC REVIEW OF ECONOMIC OUTCOMES ASSOCIATED WITH USE OF TOPICAL INTERVENTIONS FOR TREATMENT OF CHRONIC WOUNDS**
 Fatoye F, Betts A, Gebrye T, Odeyemi I, Yeowell G, Manchester Metropolitan University, Manchester, UK
- PMD91 B38 AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG) RECOMMENDATIONS FOR NEWBORN SCREENING (NBS) FOR BIOTINIDASE DEFICIENCY (BIOT): THE INFLUENCE OF UNCERTAINTY DUE TO MISSING DATA**
Kodeih R, Rittenhouse B, MCPHS University, Boston, MA, USA
- PMD92 B39 REAL LIFE USE OF DRESSINGS IN THE TREATMENT OF LEG ULCERS AND DIABETIC FOOT ULCERS**
Betts A¹, Odeyemi I¹, Fatoye F¹, Yeowell G¹, Tadej M², Lant C²,¹Manchester Metropolitan University, Manchester, UK, ²Urigo Medical Ltd, Loughborough, UK
- PMD93 B40 REPORTING OF "BENEFIT-RISK" STUDIES FOR MEDICAL DEVICES IN PUBLISHED LITERATURE**
Ritchev ME, Hollis KA, Hauber AB, Gilsenan A, Krueger WS, RTI Health Solutions, Research Triangle Park, NC, USA
- PMD94 B41 ACCOUNTING FOR KNOWN UNKNOWN IN THE AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG) RECOMMENDATIONS FOR NBS: POLICY IMPLICATIONS OF ACCOUNTING FOR UNCERTAINTY IN ASSESSMENT IN THE CASE OF MEDIUM CHAIN KETOACYL-COA THIOLASE DEFICIENCY (MCKAT) NEWBORN SCREENING (NBS)**
Rittenhouse B, MCPHS University, Boston, MA, USA
- PMD96 B42 DIFFUSION WITHOUT EVIDENCE: A STUDY ON HIGH-RISK MEDICAL DEVICES**
Armeni P¹, Torbica A², Tarricone R¹, Drummond M³,¹SDA Bocconi School of Management, Milan, Italy, ²Bocconi University, Milano, Italy, ³University of York, Heslington, York, UK
- PMD97 B43 REIMBURSEMENT LANDSCAPE FOR MOLECULAR TESTING IN NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UNITED STATES**
Nellesen D¹, Patton C¹, Mutebi A², Culver KW²,¹Analysis Group, Inc, Menlo Park, CA, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- PMD98 B44 FINANCIAL BENEFIT OF A NEW ULTRASONIC ENERGY DEVICE IN OPEN AND LAPAROSCOPIC PROCEDURES**
Park HJ, Kwak M, Johnson and Johnson Medical, Seoul, Korea, Republic of (South)
- PMD99 B45 PATELLA FRACTURE: COST, COMPLICATIONS AND TREATMENTS IN THE COMMERCIAL-INSURED POPULATION**
Vanderkarr M¹, Chitnis AS², Sparks C³, Holy CE²,¹DePuy Synthes, Inc., Raynham, MA, USA, ²Johnson & Johnson, New Brunswick, NJ, USA, ³DePuy Synthes Inc., West Chester, PA, USA
- PMD100 B46 SEPTIC REVISION OF ALL KNEE COMPONENTS FOLLOWING TOTAL KNEE ARTHROPLASTY: TYPE AND PAYMENTS FOR CARE, AND INCIDENCE OF 1-YEAR RE-INFECTION AND AMPUTATION.**
Lerner J¹, Chitnis AS², Holy CE²,¹Johnson & Johnson Medical Devices, Raynham, MA, USA, ²Johnson & Johnson, New Brunswick, NJ, USA
- PMD101 C1 HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS AMONG PATIENTS RECEIVING TREATMENT FOR PELVIC FRACTURES**
Chitnis AS¹, Childers C², Vanderkarr M³, Sparks C⁴, Folly E¹, Holy CE¹,¹Johnson & Johnson, New Brunswick, NJ, USA, ²DePuy Synthes, West Chester, PA, USA, ³DePuy Synthes, Inc., Raynham, MA, USA, ⁴DePuy Synthes Inc., West Chester, PA, USA
- PMD102 C2 COST AND SHELF-LIFE IMPLICATIONS OF PATHOGEN-REDUCED PLATELETS: A HOSPITAL BUDGET IMPACT MODEL**

Prioli KM¹, Lyons NM², Karp JK³, Herman JH³, Pizzi LT¹,¹Rutgers University, Piscataway, NJ, USA, ²Thomas Jefferson University, Philadelphia, PA, USA, ³Thomas Jefferson University Hospital, Philadelphia, PA, USA

PMD103 C3 CLINICAL AND ECONOMIC IMPACT OF SWITCHING FROM NEGATIVE- OR NEUTRAL DISPLACEMENT NEEDLELESS CONNECTORS TO POSITIVE DISPLACEMENT NEEDLELESS CONNECTORS IN CENTRAL VASCULAR ACCESS SETTINGS

Gala S¹, Erdal EP², Tuttle R³,¹BD, Franklin Lakes, NJ, USA, ²Becton Dickinson and Co., Franklin Lakes, NJ, USA, ³Becton Dickinson and Co., Sandy, UT, USA

PMD104 C4 REAL-WORLD INFECTION AND NON-UNION RATES ASSOCIATED WITH CLOSED OR OPEN FRACTURES OF THE TIBIAL SHAFT REQUIRING OPEN REDUCTION AND INTERNAL FIXATION

Chitnis AS¹, Vanderkarr M², Sparks C³, McGlohorn J⁴, Holy CE¹,¹Johnson & Johnson, New Brunswick, NJ, USA, ²DePuy Synthes, Inc., Raynham, MA, USA, ³DePuy Synthes Inc., West Chester, PA, USA, ⁴DePuy Synthes, West Chester, PA, USA

PMD105 C5 FEMORAL SHAFT FRACTURES: TREATMENT COSTS AND COMPLICATION RISKS – A CLAIMS DATABASE ANALYSIS

Holy CE¹, Vanderkarr M², Chitnis AS¹, Sparks C³,¹Johnson & Johnson, New Brunswick, NJ, USA, ²DePuy Synthes, Inc., Raynham, MA, USA, ³DePuy Synthes Inc., West Chester, PA, USA

PMD106 C6 COMPLICATIONS, HEALTH CARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH TYPE III OPEN FRACTURES OF THE TIBIAL SHAFT REQUIRING OPEN REDUCTION AND INTERNAL FIXATION

Chitnis AS¹, Vanderkarr M², Sparks C³, McGlohorn J⁴, Holy CE¹,¹Johnson & Johnson, New Brunswick, NJ, USA, ²DePuy Synthes, Inc., Raynham, MA, USA, ³DePuy Synthes Inc., West Chester, PA, USA, ⁴DePuy Synthes, West Chester, PA, USA

PMD107 C7 TRENDS IN UTILIZATION OF ENDOVASCULAR ARTERIAL REVASCLARIZATION MODALITIES BELOW THE KNEE IN GERMANY 2009-16

Geisler BP¹, Weber SA², Pietzsch M³, Pietzsch JB¹, Zeller T⁴,¹Wing Tech Inc., Menlo Park, CA, USA, ²Cellogic GmbH, Berlin, Germany, ³Wingtec GmbH, Karlsruhe, Germany, ⁴Universitaets-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany

PMD108 C8 SURGICAL PROCEDURES FOR KNEE OSTEOARTHRITIS- VOLUME AND COSTS AMONG THE COMMERCIALY-INSURED PATIENTS IN THE UNITED STATES

Holy CE¹, Chitnis AS¹, Escarpeta-Soriano J², Vanderkarr M³, Sparks C⁴,¹Johnson & Johnson, New Brunswick, NJ, USA, ²DePuy Synthes, West Chester, PA, USA, ³DePuy Synthes, Inc., Raynham, MA, USA, ⁴DePuy Synthes Inc., West Chester, PA, USA

PMD109 C9 A HOSPITAL BUDGET IMPACT MODEL TO ESTIMATE THE IMPACT ASSOCIATED WITH PHASIX™ AND PHASIX™ ST MESH VERSUS STRATTICETM MATRIX IN COMPLEX VENTRAL HERNIA REPAIR PROCEDURES

Hofstetter S¹, Hutcheson R², Gulyaev D³, Stern L⁴, Tripodi D⁵, Corral M⁶,¹NYU Langone, New York, NY, USA, ²Analytica Laser, Montreal, QC, Canada, ³LA-SER Analytica, Lorrach, Germany, ⁴Analytica Laser, New York, NY, USA, ⁵BD, Warwick, RI, USA, ⁶BD, Murray Hill, NJ, USA

PMD110 C10 COMPARATIVE EFFECTIVENESS OF SELF-MONITORING BLOOD GLUCOSE DEVICES WITH VARYING ISO ACCURACY STANDARDS IN INSULIN USING DIABETES PATIENTS: A RETROSPECTIVE COHORT ANALYSIS

Patidar M, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

PMD111 C11 HOSPITALIZATION COSTS FOR TREATMENT OF PERIPROSTHETIC FRACTURES OF THE KNEE USING MEDICARE CLAIMS AND A HOSPITAL BILLING DATA IN THE UNITED STATES

Chitnis AS¹, Smith B², Vanderkarr M³, Sparks C⁴, Holy CE¹,¹Johnson & Johnson, New Brunswick, NJ, USA, ²DePuy Synthes, West Chester, PA, USA, ³DePuy Synthes, Inc., Raynham, MA, USA, ⁴DePuy Synthes Inc., West Chester, PA, USA

PMD112 C12 INTERVENTIONAL RADIOLOGY TO BEDSIDE PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT: A U.S. HOSPITAL COST ANALYSIS

Kara R¹, Lemon R², Hollmann S³,¹Becton Dickinson & Co., Salt Lake City, UT, USA, ²Bard Access Systems, Salt Lake City, UT, USA, ³Cornerstone Research Group Inc., Burlington, ON, Canada

PMD113 C13 A RETROSPECTIVE ANALYSIS OF TACK USE WITH PROGRIP™ LAPAROSCOPIC SELF-FIXATING MESH AND 3DMAX™ MESH IN OUTPATIENT HOSPITAL INGUINAL HERNIA REPAIR PROCEDURES

Tripodi D¹, Zhang X², Wan Y², Berhane I², Corral M²,¹BD, Warwick, RI, USA, ²BD, Murray Hill, NJ, USA

- PMD114 C14 IMPACT OF THE HITECH ACT'S INCENTIVE PROGRAM ON THE ADOPTION OF DRUG-DRUG INTERACTION ALERTS AND ELECTRONIC PRESCRIBING IN THE AMBULATORY CARE SETTING**
Malhani MA¹, Maneno MK², Ettienne EB¹, Wingate LT¹,¹Howard University, Washington, DC, USA, ²Howard University College of Pharmacy, Washington, DC, USA
- PMD115 C15 IMPACT OF URINE DRUG TESTING AMONGST PATIENTS AT INCREASED RISK OF DRUG-DRUG INTERACTIONS**
Schrecker J¹, Hild C¹, Robert T¹, Layton AJ², Tang J³, **Arnold RJ**³,¹Aegis Sciences Corporation, Nashville, TN, USA, ²Navigant Consulting, Inc., San Francisco, TN, USA, ³Navigant Consulting, Inc., San Francisco, CA, USA
- PMD116 C16 SYSTEMATIC REVIEW ON CLINICAL AND HEALTH ECONOMIC BENEFIT OF USING SAFE BLOOD DRAWING DEVICE**
Xu H¹, Jiang L², Tao L³,¹Becton, Dickinson and Company, Shanghai, China, ²Sun Yat-sen University, Guangzhou, China, ³Sun Yat-Sen University, Guangzhou, China
- PMD117 C17 DEMOGRAPHIC VARIATION OF HEPATITIS C VIRUS (HCV) PREVALENCE IN THE US: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2009 – 2016**
Oziqbu CE¹, Adeyinka DA², Olakunde BO³, Olatosi BA¹,¹University of South Carolina, Columbia, SC, USA, ²University of Saskatchewan, Saskatoon, SK, Canada, ³University of Nevada, Las Vegas, NV, USA
- PMD119 C18 A SYSTEMATIC ASSESSMENT OF BUDGET IMPACT MODELS FOR MEDICAL DEVICES**
Basu R, Alsumali A, Medtronic, Mansfield, MA, USA
- PMD120 C19 FEMININE HYGIENE PRODUCT USE AND AWARENESS AMONG YOUNG US ADULTS**
Rai P¹, Shah D¹, Kelly K²,¹West Virginia University, School of Pharmacy, Morgantown, WV, USA, ²West Virginia University, Morgantown, WV, USA
- PMD121 C20 ASSESSMENT OF THE USE OF PHARMACOGENETICS IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA: RESULTS FROM A SURVEY OF PSYCHIATRISTS**
Desmond S¹, Gavaghan M¹, Howe T²,¹GfK, Waltham, MA, USA, ²GfK UK, London, UK
- PMD122 C21 DEVELOPMENT OF A COORDINATED REGISTRY NETWORK FOR WOMEN'S HEALTH TECHNOLOGIES**
Baird CE¹, Marinac-Dabic D², Darbouze F³, Lang L⁴, Dumont D⁵, Sedrakyan A¹,¹Weill Cornell Medicine, New York, NY, USA, ²U.S. Food and Drug Administration, Silver Spring, MD, USA, ³Office of the National Coordinator for Health Information Technology (ONC), Washington, DC, USA, ⁴National Library of Medicine (NLM), Bethesda, MD, USA, ⁵U.S. Food and Drug Administration, Division of Epidemiology, Office of Surveillance and Biometrics, Silver Spring, MD, USA

DISEASE- SPECIFIC STUDIES

INFECTION - Clinical Outcomes Studies

- PIN1 C22 READMISSION RISK AND ANTIBIOTIC TREATMENT FAILURE ASSOCIATED WITH HOSPITAL ACQUIRED COLOSTRUM DIFFICILE**
Craver C, Belk K, Vizient Inc., Mooresville, NC, USA
- PIN2 C23 A NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL SUGGESTS A BETTER CONTROL OF THE VIRAL LOAD VERSUS NEURAMINIDASE INHIBITORS IN THE TREATMENT OF INFLUENZA IN OTHERWISE HEALTHY PATIENTS**
Taieb V¹, Borkowska K², Ma F³, Tone K⁴, Ikeoka H⁵,¹Creativ-Ceutical, London, UK, ²Creativ-Ceutical, Cracow, Poland, ³Creativ-Ceutical, Beijing, China, ⁴Shionogi Limited, London, UK, ⁵Shionogi & Co., Ltd., Osaka, Japan
- PIN3 C24 ACUTE INFECTION FOLLOWING TRANSFUSION AMONG INPATIENT ELDERLY IN THE U.S., AS RECORDED BY LARGE ADMINISTRATIVE DATABASES DURING 2012-2017**
Menis M¹, Izurieta HS¹, Kessler Z², Kim B², McKean S², Warnock R², Verma S², Phua Y², Yi A², Kelman JA³, Anderson SA¹, Forshee RA¹,¹FDA, Silver Spring, MD, USA, ²Acumen LLC, Burlingame, CA, USA, ³CMS, Baltimore, MD, USA
- PIN4 C25 COMORBIDITY AND TREATMENT BURDEN AMONG HIV-INFECTED PATIENTS IN A US MEDICAID POPULATION**
DerSarkissian M¹, Bhak R¹, Oglesby AK², Priest J², Gao E¹, Machecha M¹, Sharperson C¹, Laliberté F³, Duh MS¹,¹Analysis Group, Inc., Boston, MA, USA, ²ViiV Healthcare, Durham, NC, USA, ³Groupe d'analyse, Ltée, Montreal, QC, Canada
- PIN5 C26 RISK OF CARDIOVASCULAR DISEASE AMONG PATIENTS WITH HEPATITIS C VIRUS (HCV) INFECTION**

Di Giuseppe G¹, **Arora P**¹, Badawi A²,¹University of Toronto, Toronto, ON, Canada, ²Public Health Agency of Canada, Toronto, ON, Canada

PIN6 C27 PREVALENCE OF ESBL KLEBSIELLA PNEUMONIAE INFECTIONS IN NIGERIA: A SYSTEMATIC REVIEW

Abubakar U¹, Syed Sulaiman SA²,¹Department of Clinical Pharmacy, Faculty of Pharmaceutical science, Universiti Sains Malaysia, penang, Malaysia, ²Universiti Sains Malaysia, Penang, Malaysia

PIN7 C28 DENGUE VACCINE EFFICACY: A SYSTEMATIC REVIEW

Santos M, Tura BR, Silveira LT, Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil

PIN8 C29 TREATMENT OUTCOMES OF VISCERAL LEISHMANIASIS IN ETHIOPIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Bhagavathula AS, Gebreyohans EA, Abegaz TM, University of Gondar, Gondar, Ethiopia

PIN9 C30 BASELINE KNOWLEDGE ABOUT VACCINES AND VACCINE-PREVENTABLE DISEASES AMONG OLDER ADULTS: PRELIMINARY BASELINE ANALYSIS OF THE VACCINE EDUCATION THROUGH PHARMACISTS AND SENIOR CENTERS (VEPSC) STUDY

Prioli KM¹, Formal R¹, Schafer JJ², Fields Harris L³, Jackson F³, Vertsman R¹, Pizzi LT¹,¹Rutgers University, Piscataway, NJ, USA, ²Thomas Jefferson University, Philadelphia, PA, USA, ³Center in the Park, Philadelphia, PA, USA

PIN10 C31 ANTI-MALARIAL TREATMENT OUTCOMES IN ETHIOPIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Seid MA, University of Gondar, Gondar, Ethiopia

PIN11 C32 THE COMPARATIVE EFFICACY, SAFETY, AND REACTOGENICITY, OF HERPES ZOSTER VACCINES: A NETWORK META-ANALYSIS

McGirr A¹, Widenmaier R¹, Curran D², Espie E², Mrkvan T², Oostvogels L², Simone B³, McElhaney J⁴, Haeussler K⁵, Thanos A⁶, Newson R⁶,¹GSK Canada, Mississauga, ON, Canada, ²GSK, Wavre, Belgium, ³GSK UK, Uxbridge, UK, ⁴Health Sciences North Research institute, Sudbury, ON, Canada, ⁵Mapi Group, München, Germany, ⁶Mapi Group, Houten, The Netherlands

PIN12 C33 THERAPEUTIC EFFICACY OF ARTEMETHERLUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN ETHIOPIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Ayalew mB, university of gondar, gondar, Ethiopia

PIN13 C34 EFFECT OF VITAMIN D SUPPLEMENTATION ON HIV OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Abariga SA¹, Poudel KC²,¹University of Maryland, Baltimore, MD, USA, ²University of Massachusetts, Amherst, MA, USA

PIN14 C35 ADVERSE DRUG REACTIONS (ADRS) ASSOCIATED WITH MEDICATIONS USED TO TREAT HIV/AIDS: 2001-PRESENT

Jackson M, Florida A & M University, Tallahassee, FL, USA

PIN15 C36 ANTIBIOTIC UTILIZATION REVIEW IN A TERTIARY INSTITUTION IN SOUTHERN NIGERIA

Temedie TC¹, **Ekwunife OI**²,¹University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria, ²Nnamdi Azikiwe University, AWKA, Nigeria

PIN16 C37 HEPATITIS C PATIENT CHARACTERISTICS ACROSS ANTIVIRAL TREATMENT ERAS IN A LARGE MANAGED CARE ORGANIZATION

Tabano DC¹, Nair K¹, Pyle L², McQueen RB¹, Truesdale AE², Steiner JF³, Anderson HD¹,¹University of Colorado Denver, Aurora, CO, USA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, USA, ³Kaiser Permanente Colorado, Denver, CO, USA

PIN17 C38 GLOBAL BURDEN OF SEASONAL INFLUENZA DISEASE: A STRUCTURED LITERATURE REVIEW

Thokagevistik K¹, Aballéa S¹, Tone K², Ikeoka H³,¹Creativ-Ceutical, Paris, France, ²Shionogi Limited, London, UK, ³Shionogi & Co., Ltd., Osaka, Japan

PIN18 C39 EPIDEMIOLOGY OF MENINGOCOCCAL DISEASE AMONG INDIVIDUALS IN A MANAGED CARE POPULATION OVER A 17-YEAR PERIOD (1999-2016)

Sharpsten L, Buikema AR, Optum, Eden Prairie, MN, USA

PIN19 C40 BURDEN OF GENITAL WARTS IN COLOMBIA: AN OBSERVATIONAL STUDY

Luna Rios JG¹, Rojas M², Cashat-Cruz M³, Yen GP⁴, Altland A⁴, Monsanto H⁵, **Beltran C**²,¹Fundación Universitaria Sanitas, Bogota, Colombia, ²Merck Sharp & Dohme, Bogota, Colombia, ³Merck Sharp & Dohme

SRL de CV, Mexico City, Mexico, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, ⁵Merck Sharp & Dohme (IA) LLC, Carolina, PR, USA

PIN20 C41 RESPIRATORY ILLNESS (RI) AND RESPIRATORY SYNCYTIAL VIRUS (RSV)-RELATED HOSPITALIZATION (RSVH) IN INFANTS WITH CONGENITAL DIAPHRAGMATIC HERNIA (CDH) IN THE CARESS REGISTRY (2005-2017)

Kim D¹, Saleem M¹, Paes B², Mitchell I³, Lanctôt KL^{1,1}Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³University of Calgary, Calgary, AB, Canada

PIN21 C42 FACTORS ASSOCIATED WITH LATE PRESENTATION FOR HIV CARE AMONG ANTIRETROVIRAL THERAPY CLINIC REGISTRANTS IN EASTERN GHANA: AN ANALYTIC CROSS SECTIONAL STUDY, 2013

Addai L¹, Davies-Teye B², Anim-Boamah K³, Sarpong C³, Akweongo P^{4,1}Eastern Regional Hospital, Ghana Health Service, Koforidua, Ghana, ²Ghana Health Service and Drifney Consult Ltd, Accra, Ghana, ³Ghana Health Service, Koforidua, Ghana, ⁴University of Ghana, Accra, Ghana

PIN22 C43 EPIDEMIOLOGY OF YOUNG INFANT GROUP B STREPTOCOCCAL DISEASE IN CHINA

Ji W¹, Liu H², Fang Y^{1,1}Xi'an Jiaotong University, Xi'an, China, ²Guangzhou Medical University, Guangzhou, China

PIN23 C44 ADHERENCE TO ANTIRETROVIRALS IN MEDICAID-INSURED PATIENTS LIVING WITH HIV: PREDICTORS AND ECONOMIC CONSEQUENCES

Dunn K¹, Lafeuille M², Jiao X¹, Romdhani H², **Emond B**², Woodruff K¹, Pesa J¹, Tandon N¹, Lefebvre P^{2,1}Janssen Scientific Affairs, LLC, Titusville, NJ, USA, ²Analysis Group, Inc., Montréal, QC, Canada

PIN24 C45 HEPATITIS B VIRUS (HBV) VACCINE IN PREGNANCY AND IMPACT ON PREGNANCY OUTCOME

Covington D¹, Kaydo S^{2,1}Evidera, Bethesda, MD, USA, ²University of North Carolina Wilmington, Wilmington, NC, USA

INFECTION - Cost Studies

PIN25 C46 ECONOMIC IMPACT OF GENERIC ANTIRETROVIRALS IN FRANCE FOR HIV PATIENT'S CARE: A SIMULATION BETWEEN 2018 AND 2022

Costa N¹, Mounie M¹, Demeulemeester R², Bernhard G³, Dellamonica P⁴, Cuzin L⁵, Allavena C⁶, Pugliese P⁷, Saint-Pierre P⁸, Molinier L⁹, Savy N^{8,1}University Hospital of Toulouse, Toulouse, France, ²University of Toulouse III, Toulouse, France, ³University hospital of Toulouse, Toulouse, France, ⁴University of Nice Sophia Antipolis, Nice, France, ⁵University hospital of Martinique, Fort de France, France, ⁶University Hospital of Nantes, Nantes, France, ⁷University hospital of Nice, Nice, France, ⁸Toulouse Mathematics Institute, Toulouse, France, ⁹Centre Hospitalier Universitaire, Toulouse, France

PIN26 D1 BUDGET IMPACT ANALYSIS OF MALARIA VACCINE IN CHILDREN YOUNGER THAN 5 YEARS IN RWANDA: A DONOR PERSPECTIVE

Ndikumukiza C, Yunusa I, Eguale T, MCPHS University, Boston, MA, USA

PIN27 D2 BUDGET IMPACT ANALYSIS OF ORITAVANCIN FOR THE TREATMENT OF MODERATE TO SEVERE ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI) FROM A HOSPITAL PERSPECTIVE

Garg M¹, Venugopalan V¹, Premraj S², Park H^{1,1}University of Florida, Gainesville, FL, USA, ²Sacred Heart Hospital, Pensacola, FL, USA

PIN28 D3 COST ESTIMATES OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE MANAGEMENT IN THE UNITED STATES - A LITERATURE REVIEW

Sugrue D¹, Ward T¹, Darlington O¹, McEwan P¹, Oglesby AK², Lopes SI^{3,1}Health Economics & Outcomes Research Ltd, Cardiff, UK, ²ViiV Healthcare, Durham, NC, USA, ³ViiV Healthcare, London, UK

PIN29 D4 ECONOMIC IMPACT OF DENGUE IN BRAZIL OVER 10 YEARS (2008-2017)

Boiron L¹, Durand L², **Araujo RR**^{1,1}Sanofi Pasteur, São Paulo, Brazil, ²Sanofi Pasteur, Ciudad de México, Mexico

PIN30 D5 THE ECONOMIC BURDEN OF VARICELLA IN MEXICO

Vazquez M¹, **Perezbolde C**², Monsanto H³, Rampakakis E⁴, Altland A³, Wolfson LJ³, Pastor V^{2,1}Natioanl Institute of Pediatrics, Mexico, Mexico, ²Merck Sharp & Dohme, Mexico City, Mexico, ³Merck & Co., Inc., Kenilworth, NJ, USA, ⁴JSS Medical Research, Montreal, QC, Canada

PIN31 D6 EVIDENCE MAP OF ECONOMIC AND HUMANISTIC BURDEN STUDIES IN PNEUMOCYSTIC PNEUMONIA.

Springate CE, Crystallise, East Tilbury, UK

- PIN32 D7 THE IMPORTANCE OF REAL WORLD DATA FOR HEALTHCARE RESOURCE PLANNING: THE CASE OF SICILIAN HCV NETWORK**
Cartabellotta F¹, Aru C², Di Giuseppe F², Di Marco V³, Integlia D², Pompilio G²,¹Unit of Internal Medicine, Buccheri La Ferla Hospital, Palermo, Italy, ²ISHEO Srl, Rome, Italy, ³Unit of Gastroenterology, Di.Bi.Mis, University of Palermo (ON BEHALF OF RESIST - HCV Network), Palermo, Italy
- PIN33 D8 COST-BENEFIT ANALYSIS OF HEPATITIS B VACCINATION STRATEGIES FOR PREVENTING MOTHER-TO-CHILD TRANSMISSION : A DECISION TREE-MARKOV MODEL**
 Yang N, Meng Y, Zhou N, Lei L, **Hu M**, Sichuan University, Chengdu, China
- PIN34 D9 PNEUMOCOCCAL VACCINES PRODUCE SUBSTANTIAL COST-SAVINGS IN MEXICO**
 Baez-Revueltas FB¹, **Serrano Galan CE**¹, Wasserman M², Grajales AG¹, Palacios MG¹,¹Pfizer Inc., Mexico City, Mexico, ²Pfizer Inc., New York, NY, USA
- PIN35 D10 COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS IN COLOMBIA**
 Lasalvia P¹, Rosselli D², Castañeda-Cardona C¹, Garzon J³, Hernández F¹, **Beltran C**⁴, Rojas M⁴, Lopez MC⁵, Sarpong EM⁶,¹NeuroEconomix, Bogota, Colombia, ²Pontificia Universidad Javeriana, Bogotá, Colombia, ³Hospital San Ignacio, BOGOTA, Colombia, ⁴Merck Sharp & Dohme, Bogota, Colombia, ⁵Merck Sharp & Dohme, Bogota, Colombia, ⁶MERCK & CO.,In., Rabway, NJ, USA
- PIN36 D11 COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM PLUS METRONIDAZOLE AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN COLOMBIA**
 Lasalvia P¹, Rosselli D², Castañeda-Cardona C¹, Garzon J³, Hernández F¹, **Beltran C**⁴, Rojas M⁴, Lopez MC⁵, Sarpong EM⁶,¹NeuroEconomix, Bogota, Colombia, ²Pontificia Universidad Javeriana, Bogotá, Colombia, ³Hospital San Ignacio, BOGOTA, Colombia, ⁴Merck Sharp & Dohme, Bogota, Colombia, ⁵Merck Sharp & Dohme, Bogota, Colombia, ⁶MERCK & CO.,In., Rabway, NJ, USA
- PIN37 D12 THE FEASIBILITY OF UTILIZING PHARMACOGENOMICS-BASED TESTING TECHNIQUES IN THE TREATMENT OF HIV/AIDS: A SYSTEMATIC REVIEW.**
Jackson M¹, Williams K¹, Ali AA¹, Diaby V²,¹Florida A & M University, Tallahassee, FL, USA, ²University of Florida, Gainesville, FL, USA
- PIN38 D13 COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN VERSUS FLUCONAZOLE FOR INVASIVE CANDIDIASIS IN MALAYSIA**
Neoh CF¹, Mohd Saad MF², Ismail H¹, Mohammed AH², Hong YH³, Kong DC⁴,¹Universiti Teknologi MARA, Malaysia, Puncak Alam, Malaysia, ²Universiti Teknologi MARA, Puncak Alam, Malaysia, ³University of Malaya, Kuala Lumpur, Malaysia, ⁴Monash University, Victoria, Australia
- PIN39 D14 COST-EFFECTIVENESS OF BIO-CELLULOSE WOUND DRESSING FOR THE TREATMENT OF CHRONIC VENOUS LEG ULCERS IN BRAZIL**
 Senna K, Leite P, Parreira V, **Santos M**, Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil
- PIN41 D15 COST-EFFECTIVENESS EVALUATION OF ERTAPENEM IN THE TREATMENT OF ADULT PATIENTS WITH COMMUNITY-ACQUIRED COMPLICATED INTRAABDOMINAL INFECTION**
 Romero M¹, Carrasquilla-Sotomayor M¹, Barrera J¹, Ruiz J², **Beltran C**³, Lopez MC², Rojas M³,¹Fundación Salutia, Bogotá D.C., Colombia, ²Merck Sharp & Dohme, Bogota, Colombia, ³Merck Sharp & Dohme, Bogota, Colombia
- PIN42 D16 COST-EFFECTIVENESS OF A 10-YEAR REVACCINATION WITH TETANUS TOXOID, REDUCED DIPHTHERIA TOXOID, AND ACELLULAR PERTUSSIS (TDAP) VACCINE AMONG INDIVIDUALS WITH PRE-EXISTING ASTHMA IN THE UNITED STATES**
 Talbird SE¹, Hoge CS², Meyers J¹, Carrico J¹, **Buck PO**²,¹RTI Health Solutions, Research Triangle Park, NC, USA, ²GSK, Philadelphia, PA, USA
- PIN43 D17 PUBLIC HEALTH AND ECONOMIC VALUE OF DENGUE VACCINATION IN BRAZIL**
Araujo RR¹, Boiron L¹, Durand L², Olivera-Botello G³, Coudeville L³,¹Sanofi Pasteur, São Paulo, Brazil, ²Sanofi Pasteur, Ciudad de México, Mexico, ³Sanofi Pasteur, Lyon, France
- PIN44 D18 COST-EFFECTIVENESS EVALUATION OF ERTAPENEM IN THE TREATMENT OF ADULT PATIENTS WITH COMMUNITY-ACQUIRED COMPLICATED URINARY TRACT INFECTIONS.**
 Romero M¹, Barrera J¹, Carrasquilla-Sotomayor M¹, Ruiz J², Lopez MC², Rojas M³, **Beltran C**²,¹Fundación Salutia, Bogotá D.C., Colombia, ²Merck Sharp & Dohme, Bogota, Colombia, ³Merck Sharp & Dohme, Bogota, Colombia
- PIN45 D19 A COST-UTILITY ANALYSIS OF ATOVAQUONE-PROGUANIL VS. ARTEMETHER-LUMEFANTRINE FOR THE TREATMENT OF UNCOMPLICATED MALARIA IN THE UNITED STATES**

N'Dri L¹, Higa S²,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Washington, Seattle, WA, USA

PIN46 D20 COST-MINIMIZATION ANALYSIS OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) MEDICATIONS FOR MRSA PNEUMONIA IN JAPAN

Nakagawa N, Ohu University, Koriyama, Fukushima, Japan

PIN47 D21 COST-EFFECTIVENESS ANALYSIS OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DUAL) FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN CHINA

CHENG W, **Chen W**, Fudan University, Shanghai, China

PIN48 D22 TRENDS IN HOSPITALIZATION LENGTH OF STAY, SEASONALITY AND COSTS IN PATIENTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES

Aggarwal S¹, Kumar S², Topaloglu O¹,¹NOVEL Health Strategies, Chevy Chase, MD, USA, ²Institute for Global Policy, Washington, DC, USA

PIN49 D23 HOSPITAL LENGTH OF STAY AND COSTS IN PATIENTS WITH POST OPERATIVE WOUND INFECTION: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES

Aggarwal S¹, Kumar S², Topaloglu O¹,¹NOVEL Health Strategies, Chevy Chase, MD, USA, ²Institute for Global Policy, Washington, DC, USA

PIN50 D24 TRENDS IN HOSPITALIZATION LENGTH OF STAY, SEASONALITY AND COSTS IN PATIENTS WITH INFLUENZA INFECTION: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES

Aggarwal S¹, Kumar S², Topaloglu O¹,¹NOVEL Health Strategies, Chevy Chase, MD, USA, ²Institute for Global Policy, Washington, DC, USA

INFECTIOUS - Patient-Reported Outcomes & Patient Preference Studies

PIN51 E1 EVALUATION ON USE OF DIGITAL REFILL REMINDERS ON PATIENT ADHERENCE TO ANTIRETROVIRAL MEDICATIONS

Hou JG¹, Hazen R², Kirkham H², Pietrandoni G², Delpino A²,¹Walgreen Co., Deerfield, IL, USA, ²Walgreen Co. Member of Walgreens Boots Alliance, Deerfield, IL, USA

PIN52 E2 ADAPTION AND VALIDATION OF THE ADHERENCE BARRIERS QUESTIONNAIRE FOR HIV PATIENTS WITH ANTIRETROVIRAL THERAPY

Mueller S¹, **Wilke T**¹, Erhart M², Kittner JM²,¹Ingress-Health HWM GmbH, Wismar, Germany, ²Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany

PIN53 E3 SELF-REPORTED ADHERENCE AND ASSOCIATED FACTORS TO ISONIAZID PREVENTIVE THERAPY FOR LATENT TUBERCULOSIS AMONG PEOPLE LIVING WITH HIV/AIDS AT HEALTH CENTERS IN GONDAR TOWN, NORTH WEST ETHIOPIA

Gebresillassie BM, Ayele AA, University of Gondar, gondar, Ethiopia

PIN54 E4 ANALYSIS OF MEDICATION ADHERENCE AMONG PATIENTS TAKING DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C

Margusino-Framiñán L, Castro-Iglesias A, Mena-de-Cea A, Cid-Silva P, Pernas-Souto B, Rodriguez-Osorio I, Vazquez-Rodriguez P, Lopez-Calvo S, Sanclaudio-Luhia I, Castro-Castro JA, Martin-Herranz I, A CORUÑA HOSPITAL, A CORUÑA, Spain

PIN55 E5 ESTIMATING HEALTH OUTCOMES IN HIV INFECTED PATIENTS TREATED WITH A DUAL REGIMEN OF DOLUTEGRAVIR AND RILPIVIRINE IN EUROPE

Darlington O¹, Lopes SI², Ward T¹, Sugrue D¹, McEwan P¹, Martin AA³, Puneekar YS⁴,¹Health Economics & Outcomes Research Ltd, Cardiff, UK, ²ViiV Healthcare, London, UK, ³GSK, Uxbridge, UK, ⁴ViiV Healthcare, Brentford, Middlesex, UK

PIN56 E6 COST AND UTILITY IN RECIPIENTS OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT (AUTO-HSCT) WHO DEVELOPED HERPES ZOSTER (HZ) DURING THE PHASE 3 TRIAL OF INACTIVATED VARICELLA-ZOSTER VACCINE (ZV_{IN})

Eriksson J¹, Hunger M², Bourhis F³, Thorén R¹, Finelli L⁴, Popmihajlov Z⁵, Jiang Y⁶,¹Mapi (an ICON plc company), Stockholm, Sweden, ²Mapi, an ICON plc company, Munich, Germany, ³Mapi (an ICON plc company), Nanterre, France, ⁴Merck & Co, Kenilworth, NJ, USA, ⁵Merck Research Laboratories, Rahway, NJ, USA, ⁶Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire, UK

PIN57 E7 PRIOR PERCEPTIONS AND SUBSEQUENT DECISIONAL CONFLICT REGARDING HIV CURE TRIAL PARTICIPATION IN BANGKOK, THAILAND

Peay H¹, Isaacson SC², Henderson GH²,¹RTI International, Research Triangle Park, NC, USA, ²The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PIN58 E8 YOUTH PREFERENCES FOR CONDITIONAL ECONOMIC INCENTIVES TO IMPROVE HIV TREATMENT ADHERENCE: A DISCRETE CHOICE EXPERIMENT IN SOUTH AFRICA

Galarraga O¹, Kuo C¹, Maughan-Brown B², Harrison A¹, Hoare J²,¹Brown University, Providence, RI, USA, ²University of Cape Town, Cape Town, South Africa

PIN59 E9 COGNITIVE DEBRIEFING INTERVIEWS TO EXPLORE THE CONTENT VALIDITY OF THE CHRONIC LIVER DISEASE QUESTIONNAIRE (CLDQ) AND EQ-5D-5L IN PATIENTS WITH CHRONIC HEPATITIS B

Kitchen H¹, Chan EK², Aldhouse NV¹, Pegram HC¹, Scott JA³,¹DRG Abacus, Manchester, UK, ²Janssen Global Services, LLC, Raritan, NJ, USA, ³Janssen Global Services, LLC, High Wycombe, UK

INFECTIOUS - Health Care Use & Policy Studies

PIN60 E10 PERCEPTION OF STUDENTS IN HEALTH PROFESSIONS TOWARDS INFLUENZA VACCINATION: A WEB-SURVEY AT A PRIVATE MIDWESTERN UNIVERSITY

Waghmare P, Siracuse M, Ohri L, Bramble J, Kaufman T, Creighton University, Omaha, NE, USA

PIN61 E11 HEPATITIS C PATIENT CHARACTERISTICS AND OVERALL CHARGES FROM AN INTEGRATED HEALTH CARE DELIVERY SYSTEM

Menon J¹, Bauer H¹, Kim J¹, Nwankwo C², Biskupiak JE¹,¹University of Utah, Salt Lake City, UT, USA, ²Merck & Co., Inc., Kenilworth, NJ, USA

PIN62 E12 ALIGNED STRATEGIES IDENTIFIED BY PRESCRIBERS AND MANAGED CARE TO CLOSE TREATMENT DECISION GAPS IN HCV AND HIV

Pardo CO, Vidret M, Viera L, Carter J, PRIME Education, Fort Lauderdale, FL, USA

PIN63 E13 VARIATION IN HEPATITIS C DRUG UTILIZATION ACROSS STATE MEDICAID PROGRAMS

Ballreich J¹, Nassery N², Segal JB³,¹Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, USA, ²Johns Hopkins University School of Medicine, Baltimore, MD, USA, ³Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

PIN64 E14 NITAG HEARS A WHO!

Wang GD, Macaulay R, PAREXEL International, London, UK

PIN65 E15 ASSESSING THE TRENDS IN THE USE OF FLUOROQUINOLONES BEFORE AND AFTER FDA NOTICE OF ITS RESTRICTED USE IN UNCOMPLICATED INFECTIONS

Gangan N¹, Stover K², Barber K², Pittman E¹, Banahan III B³, Noble S⁴,¹Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, ²University of Mississippi, Jackson, MS, USA, ³Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, MS, USA, ⁴Mississippi Division of Medicaid, Jackson, MS, USA

PIN66 E16 IMPACT OF CHLORHEXIDINE BATHING ON ANTIMICROBIAL UTILIZATION IN SURGICAL INTENSIVE CARE UNIT PATIENTS: A SECONDARY ANALYSIS OF A SINGLE-CENTER RANDOMIZED CONTROLLED TRIAL

Bui LN¹, Swan JT², Perez KK², Chen H³, Johnson ML³, Rizk E², Colavecchia AC², Graviss EA¹,¹Houston Methodist Research Institute, Houston, TX, USA, ²Houston Methodist Hospital, Houston, TX, USA, ³University of Houston, Houston, TX, USA

PIN67 E17 UPTAKE OF ALL-ORAL DIRECT ACTING ANTIVIRALS IN HEPATITIS C VIRUS-INFECTED PATIENTS WITH SUBSTANCE USE DISORDER

Jiang X, Wang W, Park H, University of Florida, Gainesville, FL, USA

PIN68 E18 EFFECTIVENESS OF THE TREATMENT WITH NEW ANTIVIRALS IN ADULT PATIENTS WITH CHRONIC INFECTION WITH HEPATITIS C VIRUS IN COLOMBIA DURING 2016-2017

Machado-Duque M¹, Granada S², Cardona-Trejos EA¹, Chica-Quintero LA¹, Machado-Alba J³,¹Universidad Tecnológica de Pereira, Pereira, Colombia, ²IPS Especializada, Pereira, Colombia, ³Universidad Tecnológica de Pereira-Audifarma S.A., Pereira, Colombia

PIN69 E19 PREVALENCE OF PNEUMOCOCCAL VACCINATION IN A RECENTLY RESETTLED REFUGEE POPULATION

Bartolome L, Payton C, Maio V, Altshuler M, Thomas Jefferson University, Philadelphia, PA, USA

PIN70 E20 PREVALENCE AND FACTORS ASSOCIATED WITH UPTAKE OF THE 3-DOSE CATCH-UP PRIMARY SERIES OF THE TETANUS-DIPHTHERIA VACCINE IN A RECENTLY RESETTLED REFUGEE POPULATION

- Voelker J¹**, Payton C², Altshuler M², Maio V¹,¹Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA, ²Thomas Jefferson University, Philadelphia, PA, USA
- PIN71 E21 MISSED OPPORTUNITIES FOR INFLUENZA AND PNEUMOCOCCAL VACCINATIONS IN THE ELDERLY IN THE US - A CROSS-SECTIONAL ANALYSIS**
Olasupo OO¹, Brown J², Segal R²,¹University of Florida, GAINESVILLE, FL, USA, ²University of Florida, Gainesville, FL, USA
- PIN72 E22 MARKET ACCESS CHALLENGES AND OPPORTUNITIES FOR ANTI-INFECTIVES: AN EU5 PERSPECTIVE**
Samuel JJ¹, Leung SK¹, Maram V², Mukku SR¹, Ohanjanyan A¹,¹Access Infinity, London, UK, ²Access Infinity, Hyderabad, India
- PIN73 E23 KNOWLEDGE, ATTITUDE AND PERCEPTION TOWARDS HUMAN PAPILLOMA VIRUS (HPV) INFECTION AND HPV VACCINATION AMONG PARENTS WITH AGE ELIGIBLE CHILDREN FOR HPV VACCINATION**
Ali AN¹, Prajapati SK², Ng YP², Iqbal MZ³, Nazer ZA⁴, Azmi S⁵, Khan AF⁶,¹AIMST University, Malaysia, bedong, Malaysia, ²AIMST University, Sungai Petani, Malaysia, ³Aimst University, Sungai Petani, Malaysia, ⁴Pfizer Hospira Health Care India Pvt Ltd, Visakhapatnam, India, ⁵USM, Penang, Malaysia, ⁶University of Veterinary and Animal Sciences, Lahore Pakistan, Lahore, Pakistan
- PIN74 E24 INAPPROPRIATE USE OF ANTIBIOTICS AMONG COMMUNITIES OF GONDAR TOWN, ETHIOPIA: A THREAT TO THE DEVELOPMENT OF ANTIMICROBIAL RESISTANCE**
Belachew SA, Mekuria aB, Erku DA,¹University of Gondar, Gondar, Ethiopia
- PIN75 F1 INFLUENZA VACCINATION IN DIABETES MELLITUS: EXPLORING PATIENT BURDEN AND STRATEGIES TO INCREASE UPTAKE**
Liska J¹, Banyon O², Samson S², Whittington C³, Murray E³, Beal A²,¹Sanofi, Paris, France, ²Sanofi, Bridgewater, NJ, USA, ³Doctor Evidence, Santa Monica, CA, USA
- PIN76 F2 VENTILATOR-ASSOCIATED PNEUMONIA: VALIDITY OF QUALITY METRICS AND OUTCOMES OF CURRENT PRACTICES**
Merola D¹, Divers C², Wen L², **Shermock KM³**,¹Shenandoah University, Winchester, VA, USA, ²Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, ³The Johns Hopkins Medical Institutions, Baltimore, MD, USA
- PIN77 F3 AGE AND RACIAL DISPARITIES IN HUMAN PAPPILOMAVIRUS (HPV) VACCINATION SERIES COMPLETION IN MISSISSIPPI MEDICAID**
Inguva S¹, Ward L², Barnard M², Pittman E¹, Banahan III B¹, Noble S³,¹Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, ²University of Mississippi, University, MS, USA, ³Mississippi Division of Medicaid, Jackson, MS, USA
- PIN78 F4 EXAMINING EPIDEMIOLOGICAL BURDEN OF SEPSIS IN THE CHINESE POPULATION USING A FOCUSED LITERATURE REVIEW**
Hou Y,¹Shenyang Pharmaceutical University, Shenyang, China
- PIN79 F5 POST-LICENSURE SURVEILLANCE OF HUMAN PAPILLOMA VIRUS (HPV) VACCINE (GARDASIL, CERVARIX AND GARDASIL 9) USING VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS), 2006-2017**
Subeesh V, Reddy N, Maheswari E, Swaroop AM,¹MS Ramaiah University of Applied Sciences, Bangalore, India
- PIN80 F6 BENCHMARKING HIV QUALITY MEASURES IN THE US OPERA HIV COHORT**
Heglar R¹, Mood R², **Priest J³**, Schulman K², Fusco G²,¹AIDS Healthcare Foundation, Miami Beach, FL, USA, ²Epidivian, Durham, NC, USA, ³ViiV Healthcare, Durham, NC, USA
- PIN81 F7 BENCHMARKING HIV QUALITY MEASURES ACROSS US PAYER TYPES**
Priest J¹, Irwin D², Evans KA², Oglesby AK¹, Brady BL³,¹ViiV Healthcare, Durham, NC, USA, ²Truven Health Analytics, an IBM Company, Bethesda, MD, USA, ³IBM Watson Health™, Bethesda, MD, USA
- PIN82 F8 EFFECTIVENESS OF GUIDELINE-RECOMMENDED CARE BUNDLES: A SYSTEMATIC REVIEW**
Merola D¹, Divers C², Wen L², **Shermock KM³**,¹Shenandoah University, Winchester, VA, USA, ²Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, ³The Johns Hopkins Medical Institutions, Baltimore, MD, USA
- PIN83 F9 HIV TREATMENT GUIDELINES AND MEDICATION INITIATION PATTERNS IN TREATMENT NAÏVE ADULTS, 2008-2016**

SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies

- PSY1 F10 EFFICACY AND INHIBITOR DEVELOPMENT OF PROPHYLACTIC VS ON-DEMAND FACTOR VIII AND IX IN THE MANAGEMENT OF HAEMOPHILIA PATIENTS FROM SOUTHEAST ASIA: A SYSTEMATIC REVIEW**
Gupta P¹, Nikam R², Pandey P², Pandey R², Dhagale P², Shah V²,¹All India Institute of Medical Sciences, Patna, India, ²SIRO Clinpharm Pvt Ltd, Maharashtra, India
- PSY2 F11 PREGABALIN USE ON DIABETIC NEUROPATHY PATIENTS AND THE RISK OF HEART FAILURE**
Hung DT, Kathe N, Painter JT, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- PSY3 F12 IDENTIFICATION OF SURGICAL BLEEDING COMPLICATIONS IN THE LINKED U.K. CLINICAL PRACTICE RESEARCH DATALINK & HOSPITAL EPISODE STATISTICS DATABASES: IMPACT OF VARYING DEFINITIONS ON INCIDENCE AND ASSOCIATION WITH HOSPITAL LENGTH OF STAY**
Ammann EM¹, Jamous N², Johnston SS¹, Mistry S², Gangoli G³, Danker III W³, Al Attar N⁴,¹Johnson & Johnson, Inc., New Brunswick, NJ, USA, ²Johnson & Johnson Medical Ltd, Berkshire, UK, ³Ethicon, Inc., Somerville, NJ, USA, ⁴Golden Jubilee National Hospital, Glasgow, UK
- PSY4 F13 INPATIENT COST AND COMPLICATIONS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN NON-HODGKIN'S LYMPHOMA (NHL)**
Cho SK, McCombs J, Punwani N, University of Southern California, Los Angeles, CA, USA
- PSY5 F14 USING MACHINE LEARNING TO PREDICT OPIOID OVERDOSES AMONG PRESCRIPTION OPIOID USERS**
Li X¹, Chaovalitwongse WA², Curran G¹, Tilford JM¹, Felix H¹, Martin BC¹,¹University of Arkansas for Medical Sciences, Little Rock, AR, USA, ²University of Arkansas, Fayetteville, Fayetteville, AR, USA
- PSY6 F15 DOSE-RESPONSE ASSOCIATION BETWEEN CONCURRENT OPIOID AND BENZODIAZEPINE USE AND RISK OF OPIOID- RELATED OVERDOSE**
Hernandez I¹, He M¹, Zhang Y²,¹University of pittsburgh, Pittsburgh, PA, USA, ²University of Pittsburgh, Pittsburgh, PA, USA
- PSY7 F16 BODY MASS INDEX AND OBESITY-RELATED COMORBIDITIES AMONG PATIENTS AGED<65 YEARS UNDERGOING BARIATRIC SURGERY: COMPARISON BETWEEN MEDICARE AND COMMERCIALY-INSURED**
Johnston SS¹, Ramiseti S¹, Sadik K², Hsiao C³, Wei D⁴, Scamuffa R³,¹Johnson & Johnson, Inc., New Brunswick, NJ, USA, ²Ethicon Inc., Somerville, NJ, USA, ³Ethicon, Inc., Cincinnati, OH, USA, ⁴Johnson & Johnson Co., New Brunswick, NJ, USA
- PSY8 F17 TRENDS IN HOSPITALIZATION CHARGES FOR PATIENTS DIAGNOSED WITH ELIXHAUSER COMORBIDITES AS A FUNCTION OF BODY MASS INDEX**
Peyeri FW, Khangulov VS, Lodaya K, Shen M, Snelson CD, D'Souza FT, Boston Strategic Partners, Inc., Boston, MA, USA
- PSY9 F18 RELATIONSHIP BETWEEN PAIN CRISIS AND LIFE-THREATENING COMPLICATIONS IN SICKLE CELL DISEASE: A RETROSPECTIVE CLAIMS BASED STUDY**
Bhor M¹, Wang Y², Xie L², Halloway R¹, Arcona S³, Paulose J¹, Ogbomo A², Shen Y², Yuce H⁴, Shah N⁵,¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ²STATinMED Research, Ann Arbor, MI, USA, ³Novartis Pharmaceuticals, East Hanover, NJ, USA, ⁴New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, ⁵Duke University School of Medicine, Durham, NC, USA
- PSY10 F19 REAL-WORLD CLINICAL EFFECTIVENESS OF LIRAGLUTIDE 3.0 MG FOR WEIGHT MANAGEMENT IN CANADA**
Wharton S¹, Liu A², Pakseresht A², Nørtoft E³, Haase CL³, Mancini J⁴, Power GS⁵, VanderLelie S¹, **Christensen RA**¹,¹Wharton Medical Clinic, Burlington, ON, Canada, ²Novo Nordisk Canada Inc., Mississauga, ON, Canada, ³Novo Nordisk A/S, Copenhagen, Denmark, ⁴IQVIA, Montreal, QC, Canada, ⁵IQVIA, Mississauga, ON, Canada
- PSY11 F20 MODEL-BASED EVALUATION OF THE EFFICACY AND SAFETY OF BUROSUMAB, A FULLY HUMAN ANTI-FGF23 MONOCLONAL ANTIBODY, IN ADOLESCENT X-LINKED HYPOPHOSPHATEMIA (XLH)**
Shi J¹, Gosselin NH², Chen C¹, Wang R¹, San Martin J¹,¹Ultragenyx Pharmaceutical Inc., Novato, CA, USA, ²Certara Strategic Consulting, Princeton, NJ, USA

- PSY12 F21 MATCHING-ADJUSTED INDIRECT COMPARISONS (MAICS) OF EFFICACY AND CONSUMPTION OF BAY 94-9027 VERSUS THREE RECOMBINANT FACTOR VIII (RFVIII) FOR PROPHYLAXIS OF SEVERE HEMOPHILIA A**
Ayyagari R¹, Deschaseaux C², **Vashi PB**³, Kessabi S², Gao W¹,¹Analysis Group, Inc., Boston, MA, USA, ²Bayer, Basel, Switzerland, ³Bayer, Whippany, NJ, USA
- PSY13 F22 NUMBER NEEDED TO TREAT IN PATIENTS WITH SPINAL MUSCULAR ATROPHY TYPE 1 TREATED WITH AVXS-101 RELATIVE TO NUSINERSEN**
Dabbous O¹, Cloutier M², Guerin A², Pivneva I², Wu EQ³, Sproule DM¹,¹AveXis, Inc., Bannockburn, IL, USA, ²Analysis Group, Inc., Montreal, QC, Canada, ³Analysis Group, Inc., Boston, MA, USA
- PSY14 F23 A COMPARISON OF PROPHYLACTIC VERSUS ON-DEMAND TREATMENT REGIMENS OF COAGULATION FACTOR VIII FOR BLEEDING AND JOINT OUTCOMES IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Oak B¹, Nambiar S¹, Springs S², Eguale T¹,¹MCPHS University, Boston, MA, USA, ²Brown University School of Public Health, Providence, RI, USA
- PSY15 F24 BAYESIAN NETWORK META-ANALYSIS OF TREATMENTS IN IRON DEFICIENCY ANAEMIA (IDA)**
Tremblay G¹, Dolph M¹, Jones T², **Forsythe A**¹,¹Purple Squirrel Economics, New York, NY, USA, ²Shield Therapeutics, London, UK
- PSY16 G1 IMPACT OF MEDICAL MARIJUANA LEGALIZATION ON OPIOID USE, CHRONIC OPIOID USE AND HIGH-RISK OPIOID USE.**
Shah AB¹, Hayes CJ¹, Lakkad M¹, Martin BC²,¹University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA, ²University of Arkansas for Medical Sciences, Little Rock, AR, USA
- PSY17 G2 EVALUATION OF OPIOID USE AMONG PATIENTS WITH BACK DISORDERS AND ARTHRITIS**
Hayes CJ¹, Payakachat N¹, Li C²,¹University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA, ²University of Arkansas for Medical Sciences, Little Rock, AR, USA
- PSY18 G3 COMPARING THE EPIDEMIOLOGY OF ADPKD IN THE US FROM 2010-2015 USING ONE VERSUS TWO DIAGNOSIS CODES IN CLAIMS DATA**
Stewart A¹, Hao L², Joly F³, Olivares R³,¹Sanofi, Cambridge, MA, USA, ²Sanofi, Bridgewater, NJ, USA, ³Sanofi, Chilly-Mazarin, France
- PSY19 G4 ALLAINCE BETWEEN OBESITY AND PSYCHIATRIC DISORDERS- A CROSS SECTIONAL EPIDEMIOLOGICAL STUDY.**
Nimmagadda S, Acharya Nagarjuna University, Guntur, India
- PSY20 G5 RELATIONSHIP BETWEEN EARLY-LIFE ANTIBIOTIC EXPOSURE AND CHILDHOOD OBESITY: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Kim S¹, Kim MG², Kim M¹, Song S¹, Yoo HJ¹, Kwon J¹, Oh JM¹, Lee E¹,¹Seoul National University, Seoul, Korea, Republic of (South), ²CHA University, Pocheon, Korea, Republic of (South)
- PSY21 G6 NATIONAL TRENDS IN UTILIZATION OF BARIATRIC SURGERY**
Alalwan A, Hartzema A, University of Florida, Gainesville, FL, USA
- PSY22 G7 REAL WORLD INCIDENCE AND PREVALENCE OF SYSTEMATIC LUPUS ERYTHEMATOSUS IN ALBERTA, CANADA**
Fatoye F, Gebrye T, Svenson L, Manchester Metropolitan University, Manchester, UK
- PSY23 G8 INCIDENCE OF REOPERATIONS AFTER LAPAROSCOPIC BARIATRIC SURGERY**
Johnston SS¹, Fegelman E², Hsiao C³,¹Johnson & Johnson, Inc., New Brunswick, NJ, USA, ²Ethicon Inc, Cincinnati, OH, USA, ³Ethicon, Inc., Cincinnati, OH, USA
- PSY24 G9 PREVALENCE AND DURATION OF SKELETAL MUSCLE RELAXANT TREATMENT AMONG COMMERCIALY INSURED ADULTS IN THE UNITED STATES FROM 2005 TO 2015**
Li Y¹, Reisfield GM², Winterstein AG¹,¹University of Florida, College of Pharmacy, Gainesville, FL, USA, ²University of Florida, College of Medicine, Gainesville, FL, USA
- PSY25 G10 NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES) ANALYSIS OF THE USA'S OBESE POPULATION AND RELATED COMORBIDITIES**
Lee S¹, Savant K², Hsiao C³,¹Thomas Jefferson University, Philadelphia, PA, USA, ²Cheers Interactive, Mumbai, India, ³Ethicon, Inc., Cincinnati, OH, USA
- PSY26 G11 A SYSTEMATIC REVIEW OF THE EPIDEMIOLOGY OF ALPHA-MANNO SIDOSIS**

Finocchiario D¹, Rastelletti I¹, De-Almeida J², Lloyd S², Gupta P³,¹Chiesi farmaceutici s.p.a., Parma, Italy, ²Chiesi Limited, Manchester, UK, ³DRG Abacus, Gurgaon, India

PSY27 G12 RELATIVE RISK AND CRUDE MORTALITY AMONG COHORTS OF US MEDICARE BENEFICIARIES WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Clark LA¹, Patel RP², Noone JM³, Blanchette CM¹, Howden R¹,¹University of North Carolina at Charlotte, Charlotte, NC, USA, ²University of North Carolina - Charlotte, Charlotte, NC, USA, ³Ipsos, Charlotte, NC, USA

PSY28 G13 MODIFIABLE RISK FACTORS AND POPULATION ATTRIBUTABLE RISK OF OBESITY AMONG HIGH SCHOOL STUDENTS IN THE U.S.

Hu EY¹, **Bhattacharya K**², Nunna S², Ramachandran S²,¹Oxford High School, Oxford, MS, USA, ²University of Mississippi, University, MS, USA

PSY29 G14 FLT3 MUTATED AND WILDTYPE ACUTE MYELOID LEUKEMIA TREATMENT PATTERNS AND OUTCOMES AT A COMPREHENSIVE CANCER CENTER

Menon J¹, Willis CW¹, Unni S¹, Au T¹, Ndife B², Joseph G², Brixner D¹, Stein EM³, Tantravahi S⁴, Shami P⁴, Kovacsovics T⁴, Stenehjem D⁵,¹University of Utah, Salt Lake City, UT, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Memorial Sloan Kettering Cancer Center, New York, UT, USA, ⁴Huntsman Cancer Institute, Salt Lake City, UT, USA, ⁵University of Utah and University of Minnesota, Salt Lake City, UT, USA

PSY30 G15 DEVELOPMENT AND VALIDATION OF A MODEL TO PREDICT CESSATION OF ANTIHYPERGLYCEMIC MEDICATION AFTER LAPAROSCOPIC BARIATRIC SURGERY AMONG PATIENTS WITH TYPE 2 DIABETES

Reps J¹, Hsiao C², **Johnston SS**³,¹Janssen Pharmaceuticals, Inc., Titusville, NJ, USA, ²Ethicon, Inc., Cincinnati, OH, USA, ³Johnson & Johnson, Inc., New Brunswick, NJ, USA

PSY31 G16 SYSTEMATIC REVIEW AND DECISION ANALYSIS FOR CURRENT AND EXPERIMENTAL THERAPIES FOR WISKOTT-ALDRICH SYNDROME

Carneiro Leao I¹, Ezzeldin H¹, Tegenge MA¹, Yang H¹, Forshee RA², Sokolic R³,¹U.S. Food and Drug Administration, Silver Spring, MD, USA, ²FDA, Silver Spring, MD, USA, ³Lifespan Health System, Providence, RI, USA

SYSTEMIC DISORDERS/CONDITIONS - Cost Studies

PSY32 G17 THE IMPACT OF JUDICIALIZATION OF ECULIZUMAB ON THE BUDGET OF BRAZILIAN HEALTH SYSTEM

Simabuku EM¹, Beutel JO¹, Souza KM¹, Biella Cd², Rabelo RB³, Brito AF¹,¹Brazilian Ministry of Health, Brasilia, Brazil, ²Brazilian Ministry of Health, Brasília, Brazil, ³Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, Brazil

PSY33 G18 EVALUATION OF SUBCUTANEOUS RITUXIMAB ADMINISTRATION IMPACTS ON CANADIAN SYSTEMIC THERAPY SUITES

Stewart D¹, Boudreault J², Maturi B³, **Boras D**³, Foley R⁴,¹University of Calgary and Tom Baker Cancer Centre, Calgary, AB, Canada, ²Hôpital universitaire du Sacré-Coeur de Montréal, Montréal, QC, Canada, ³Hoffmann-La Roche Limited, Mississauga, ON, Canada, ⁴Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada

PSY34 G19 THE BUDGET IMPACT OF DEFLAZACORT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD)

Carlton R¹, Regan T¹, **Narayanan S**²,¹Xcenda, LLC, Palm Harbor, FL, USA, ²PTC Therapeutics, Inc., South Plainfield, NJ, USA

PSY35 G20 BUDGET IMPACT OF PASIREOTIDE LAR FOR THE TREATMENT OF CUSHING'S DISEASE FROM A FINNISH SOCIETAL PERSPECTIVE

Lee KW¹, Niskanen L², Olson F³, Bornheimer R⁴, Maamari R⁵, **Neary MP**⁵,¹Novartis Ireland Limited, Dublin, Ireland, ²Helsinki University Hospital, Helsinki, Finland, ³Nordic Health Economics AB, Göteborg, Sweden, ⁴Policy Analysis Inc. (PAI), Brookline, MA, USA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PSY36 G21 ECONOMIC EVALUATION OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIII FC) FOR IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA A WHO DEVELOP INHIBITORS UNDER THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS) PERSPECTIVE

Teich V¹, Li N², Brito K², Krishnan S², Su J²,¹SENSE Company, São Paulo, Brazil, ²Bioverativ, Waltham, MA, USA

- PSY37 G22 REIMBURSEMENT OF VEDOLIZUMAB ACCORDING TO THE INDICATIONS: WHAT ARE THE IMPACTS IN THE 37 PUBLIC HOSPITALS OF PARIS?**
Peyrilles E¹, Therasse C¹, Cordonnier A¹, Paubel P², Fusier J¹,¹AP-HP, AGEPS, Paris, France, ²General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Faculté de pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, Paris, France
- PSY38 G23 ECONOMIC BURDEN OF INFANT-ONSET (TYPE 1) SPINAL MUSCULAR ATROPHY: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS**
Dabbous O¹, Seda J², Sproule DM¹,¹AveXis, Inc, Bannockburn, IL, USA, ²SSI Strategy, Parsippany, NJ, USA
- PSY39 G24 ASSESSING HOSPITAL UTILIZATION OF PATIENTS DIAGNOSED WITH MARFAN SYNDROME**
Belk K¹, Mallow P², Craver CW¹,¹Vizient Inc., Mooresville, NC, USA, ²Xavier University, Cincinnati, OH, USA
- PSY40 H1 HEALTHCARE COST OF POTENTIAL GLUCOCORTICOID-ASSOCIATED ADVERSE EVENTS IN PATIENTS WITH GIANT CELL ARTERITIS**
Best JH¹, Kong A², Smith D², Abbass I¹, Michalska M¹,¹Genentech, Inc., South San Francisco, CA, USA, ²Truven Health Analytics, an IBM Company, Bethesda, MD, USA
- PSY41 H2 THE ECONOMIC BURDEN OF SPHINGOLOPIDOSIS IN KOREA**
Heo E, Bae S, Ewha Womans University, Seoul, Korea, Republic of (South)
- PSY42 H3 THE DIRECT COST BURDEN OF TUBEROUS SCLEROSIS COMPLEX AMONG INSURED PATIENTS IN THE US**
Reaven NL¹, Funk SE¹, Story TJ²,¹Strategic Health Resources, La Canada, CA, USA, ²Greenwich Biosciences, Inc., Carlsbad, CA, USA
- PSY43 H4 ASSOCIATION BETWEEN BLEEDING EVENTS AND NON-DRUG DIRECT COSTS IN ADULTS WITH SEVERE HEMOPHILIA A**
Watt M¹, O'Hara J², Noone D², Jacob I², Booth J³,¹Shire, Zug, Switzerland, ²HCD Economics, Cheshire, UK, ³Shire, Cambridge, MA, USA
- PSY44 H5 ECONOMIC BURDEN OF MYASTHENIA GRAVIS IN THE US: A LITERATURE REVIEW**
Sharma N, Bisen R, Rawat NS, Afaque A, Gupta S, BresMed Health Solutions Pvt. Ltd., Gurugram, India
- PSY45 H6 EMERGENCY CARE IN MARFAN SYNDROME: A RETROSPECTIVE HOSPITAL ANALYSIS**
Belk K¹, Mallow P², Craver CW¹,¹Vizient Inc., Mooresville, NC, USA, ²Xavier University, Cincinnati, OH, USA
- PSY46 H7 APPROVALS AND PRICING OF FACTOR VIII AND FACTOR IX CONCENTRATES FOR HEMOPHILIA A AND B IN THE UNITED STATES**
Oak B, Eguale T, MCPHS University, Boston, MA, USA
- PSY47 H8 COSTS OF COMPLICATIONS IN LAPAROSCOPIC BARIATRIC SURGERY**
Wei D¹, Hsiao C², Johnston SS¹,¹Johnson & Johnson Co., New Brunswick, NJ, USA, ²Ethicon, Inc., Cincinnati, OH, USA
- PSY48 H9 PERCEPTIONS OF COST PRESSURE ASSOCIATED WITH BIOSIMILARS AMONG PHYSICIANS IN EUROPE**
Karki C¹, Baskett A², Baynton E², Lu Y¹, Shah-Manek B³,¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, London, UK, ³Ipsos Healthcare, San Francisco, CA, USA
- PSY49 H10 OPTIFAST® MEAL REPLACEMENT PROGRAM FOR THE TREATMENT OF OBESITY: A COST-EFFECTIVENESS ASSESSMENT FROM THE EMPLOYER PERSPECTIVE IN THE USA**
Perugini M¹, Marczevska AM¹, Araujo Torres K¹, Rasouli B², Nuijten M³,¹Nestle Health Science, Vevey, Switzerland, ²Karolinska Institutet, Stockholm, Sweden, ³A2M - Minerva, Jisp, The Netherlands
- PSY50 H11 COST-EFFECTIVENESS OF TACROLIMUS FOR THE TREATMENT OF MODERATE-TO-SEVERE LUPUS NEPHRITIS**
Kim S¹, Ooi AY¹, Stephens TJ², Jiang H¹,¹Astellas Medical Affairs Asia Oceania, Singapore, Singapore, ²Amaris Consulting UK, London, UK
- PSY51 H12 TREATMENT STRATEGIES IN CHILDREN WITH SEVERE SICKLE CELL DISEASE AFTER THE INTRODUCTION OF L-GLUTAMINE POWDER: A DECISION ANALYSIS**
Yunusa I, Ndikumukiza C, Eguale T, MCPHS University, Boston, MA, USA

- PSY53 H13 COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSUS HIGH-DOSE IMATINIB FOR THE SECOND-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHINA : BASED ON NATION-WIDE DATA**
Guan L¹, Huang C¹, Liu Y²,¹Tsinghua University, Shenzhen, China, ²China National Health Development Research Center, Beijing, China
- PSY54 H14 A HEALTH ECONOMIC MODEL FOR MYELODYSPLASTIC SYNDROME: SYSTEMATIC LITERATURE REVIEW TO INFORM CONCEPTUAL MODEL DESIGN**
 Sugrue D¹, Hayes A¹, McNamara B¹, McEwan P¹, Cunningham T², van Haalen HG³,¹Health Economics & Outcomes Research Ltd, Cardiff, UK, ²AstraZeneca, Royston, UK, ³AstraZeneca, Gothenburg, Sweden
- PSY55 H15 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) AND DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)**
 Pelligra C¹, Guo S¹, Parikh K², Zhang S¹, Krotneva M³, Onyekwere U⁴, Clancy Z²,¹Evidera, Waltham, MA, USA, ²Celgene Corporation, Summit, NJ, USA, ³Evidera, St-Laurent, QC, Canada, ⁴Evidera, Bethesda, MD, USA
- PSY56 H16 ECONOMIC EVALUATION OF DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**
 Salazar A¹, Guirant Corpi L², Aguirre A², Herrera M³, Chacon C⁴,¹Janssen Mexico, Mexico City, IL, USA, ²Janssen Mexico, Mexico City, Mexico, ³Janssen, Mexico City, Mexico, ⁴Janssen LATAM, Mexico City, Mexico
- PSY57 H17 BELIMUMAB FOR THE TREATMENT OF ADULTS LIVING WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A COST-EFFECTIVENESS ANALYSIS IN CANADA**
Mursleen S¹, Gahn JC², Klein RW², Asukai Y³,¹GSK, Mississauga, ON, Canada, ²Medical Decision Modeling Inc., Indianapolis, IN, USA, ³GSK, Brentford, UK
- PSY58 H18 AN OBSERVATIONAL STUDY OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS AND SELECTED NON-G551D GATING MUTATIONS IN UK, ITALY AND NETHERLANDS: HEALTHCARE RESOURCE UTILIZATION FROM THE FIRST INTERIM ANALYSIS OF THE VOCAL STUDY**
 Castellani C¹, Colombo C², van der Ent CK³, Simmonds NJ⁴, Kinnman N⁵, Hassan M⁶, DeSouza C⁶, Kaviya A⁵,¹Ospedale Civile Maggiore, Verona, Italy, ²University of Milan, Milan, Italy, ³University Medical Center Utrecht, Utrecht, The Netherlands, ⁴Royal Brompton Hospital, London, UK, ⁵Vertex Pharmaceuticals (Europe) Limited, London, UK, ⁶Vertex Pharmaceuticals Incorporated, Boston, MA, USA
- PSY59 H19 IMPACT OF HEMOPHILIC ARTHROPATHY ON THE CONSUMPTION OF ANTI-HEMOPHILIC FACTORS DUE TO SPONTANEOUS AND TRAUMATIC BLEEDING EVENTS IN SEVERE HEMOPHILIA PATIENTS WITHOUT THE PRESENCE OF INHIBITORS IN COLOMBIA**
 Agudelo C¹, Canon O², Lamos C³,¹Grupo Sanitas, Bogota, Colombia, ²GBT, Bogota, Colombia, ³Universidad del Bosque, Bogota, Colombia
- PSY60 H20 TRENDS IN HOSPITALIZATION LENGTH OF STAY AND COSTS IN PATIENTS WITH HEREDITARY ANGIOEDEMA: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015**
Aggarwal S¹, Kumar S², Topaloglu O¹,¹NOVEL Health Strategies, Chevy Chase, MD, USA, ²Institute for Global Policy, Washington, DC, USA
- PSY61 H21 TRENDS IN HOSPITALIZATION LENGTH OF STAY AND COSTS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015**
Aggarwal S¹, Kumar S², Topaloglu O¹,¹NOVEL Health Strategies, Chevy Chase, MD, USA, ²Institute for Global Policy, Washington, DC, USA

SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient Preference Studies

- PSY62 H22 EFFECT OF NON-ADHERENCE ON HEALTHCARE RESOURCE UTILIZATION IN FIBROMYALGIA PATIENTS: A RETROSPECTIVE COHORT STUDY**
Desai RA, Marlow N, University of Florida, Gainesville, FL, USA
- PSY63 H23 ASSOCIATION BETWEEN HYDROXYUREA MEDICATION ADHERENCE AND VASO-OCCLUSIVE CRISIS EVENTS AMONG TEXAS MEDICAID ENROLLEES WITH SICKLE CELL DISEASE**
Kang HA¹, Barner JC¹, Rascati KL¹, Lawson KA¹, Mignacca R²,¹The University of Texas at Austin, Austin, TX, USA, ²Dell Children's Blood and Cancer Center, Austin, TX, USA
- PSY64 H24 ADHERENCE ISSUES IN CROHN'S DISEASE: HOW CAN ACCEPTANCE MEASUREMENT HELP UNDERSTANDING PATIENTS' CONCERNS AND WORKING ON SOLUTIONS?**

Wiederkehr S¹, de Bock E¹, Chekroun M², **Arnould B**¹, Mapi, An ICON plc Company, Patient-Centered Outcomes, Lyon, France, ²Carenity, Paris, France

- PSY65 11 ASSESSING THE POTENTIAL IMPACT OF TREATING HYPERPHAGIA AMONG PEOPLE WITH PRADER-WILLI SYNDROME USING DISEASE-SPECIFIC QALYS**
Bridges JF¹, Lavelle T², Tsai J³, Kayadjanian N⁴, Strong T⁵, ¹The Ohio State University, Columbus, OH, USA, ²Tufts Medical Center, Boston, MA, USA, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ⁴International Consortium to Advance Clinical Trials for Prader-Willi Syndrome, Walnut, CA, USA, ⁵The Foundation for Prader-Willi Research, Walnut, CA, USA
- PSY66 12 COMPARING CLOTTING FACTORS BENEFIT-RISK ATTRIBUTES ACROSS DIFFERENT METHODS OF PREFERENCE ELICITATION IN HEMOPHILIA PATIENTS**
Tegege MA, Belov A, Moncur M, Forshee RA, Irony T, U.S. Food and Drug Administration, Silver Spring, MD, USA
- PSY67 13 PARENT AND ADULT PATIENT ATTITUDES ABOUT GENE THERAPY AS A THERAPEUTIC OPTION FOR DUCHENNE MUSCULAR DYSTROPHY**
Peay H¹, Fischer R², Beaverson K³, Morris C⁴, Hesterlee SE⁵, Ricotti V⁴, Martin A⁶, Rensch C⁷, Wand H⁸, Mansfield CA⁹, Smith E¹⁰, ¹RTI International, Research Triangle Park, NJ, USA, ²Parent Project Muscular Dystrophy (PPMD), Hackensack, NJ, USA, ³Pfizer, New York, NJ, USA, ⁴Solid Biosciences, Cambridge, MA, USA, ⁵Pfizer, Chapel Hill, NJ, USA, ⁶UCLA, Los Angeles, CA, USA, ⁷Parent Project Muscular Dystrophy, Hackensack, NJ, USA, ⁸Johns Hopkins School of Public Health, Baltimore, MD, USA, ⁹RTI Health Solutions, Research Triangle Park, NC, USA, ¹⁰Duke University, Durham, NC, USA
- PSY68 14 IDENTIFYING CAREGIVER PRIORITIES FOR TREATMENT ENDPOINTS FOR PRADER-WILLI SYNDROME WITH BEST-WORST SCALING**
Tsai J¹, Scheimann AO², McCandless SE³, Strong TV⁴, Bridges JF⁵, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ²Johns Hopkins Hospital, Baltimore, MD, USA, ³Case Western Reserve University School of Medicine, Cleveland, OH, USA, ⁴The Foundation for Prader-Willi Research, Walnut, CA, USA, ⁵The Ohio State University, Columbus, OH, USA
- PSY69 15 DEVELOPMENT AND APPLICATION OF A NOVEL PATIENT-REPORTED OUTCOMES INSTRUMENT, THE PSORIASIS SYMPTOMS AND SIGNS DIARY, MEASURING PSORIASIS SEVERITY IN CLINICAL TRIALS**
Han C¹, Song M², Wasfi Y², Li S², Needleman H², ¹Janssen Global Services, LLC, Malvern, PA, USA, ²Janssen Research & Development, LLC, Spring House, PA, USA
- PSY70 16 ROLE OF PATIENT-REPORTED OUTCOME EVALUATION IN THE APPROVAL OF ORPHAN DRUGS: A REVIEW OF 15 YEAR APPROVALS BY THE FDA AND THE EMA**
Arnould B¹, Acquadro C², Lanar S², Savre J³, ¹Mapi, An ICON plc Company, Patient-Centered Outcomes, Lyon, France, ²Mapi, An ICON plc Company, Lyon, France, ³Mapi Research Trust, Lyon, France
- PSY71 17 A QUALITATIVE STUDY TO EXPLORE THE CONTENT VALIDITY OF PATIENT-REPORTED OUTCOME MEASURES IN A SYSTEMIC LUPUS ERYTHEMATOSUS POPULATION**
Kitchen H¹, Al-Zubeidi T², Mathers LE², Paik J³, DeLozier AM³, ¹DRG Abacus, Manchester, UK, ²DRG Abacus, Oxfordshire, UK, ³Eli Lilly and Company, Indianapolis, IN, USA
- PSY72 18 DEVELOPMENT OF A PATIENT-REPORTED OUTCOME (PRO) INSTRUMENT FOR PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA**
Oladapo AO¹, Ito D¹, Hibbard C¹, Hare TM², Krupnick RN², Ewenstein BM¹, ¹Shire, Cambridge, MA, USA, ²IQVIA, Cambridge, MA, USA
- PSY73 19 EVIDENCE MAP OF PRO INSTRUMENTS ASSESSING NECK AND BACK PAIN**
Springate CE, Crystallise, East Tilbury, UK
- PSY74 110 THE BURDEN OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS ON HEALTH-RELATED QUALITY OF LIFE**
Lovley A¹, Guthrie SD², **Sikora Kessler A**¹, Yaras A¹, Pollock MR³, Patel P⁴, White MK¹, ¹Optum, Johnston, RI, USA, ²Biopharma Strategic Consulting, LLC, San Francisco, CA, USA, ³Reynolds Pollock & Associates, Sacramento, CA, USA, ⁴Kantar Health, New York, NY, USA
- PSY75 111 PATIENT OUTLOOK AND PRACTICE IN IRON DEFICIENCY ANEMIA: A PROSPECTIVE OBSERVATIONAL QUESTIONNAIRE BASED STUDY**
Bhat D¹, G R S², Chalasani SH³, ¹M. S. Ramaiah College of Pharmacy, Bangalore, India, ²Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bangalore, India, ³JSS College of Pharmacy, Mysuru, India

- PSY76 I12 US LUPUS TRENDS 2009-2017: RESULTS FROM THE NATIONAL HEALTH AND WELLNESS SURVEY**
LaPrade A¹, Annunziata K¹, Sternbach N², **Patel P**¹,¹KANTAR HEALTH, NEW YORK CITY, NY, USA, ²Kantar Health, New York City, NY, USA
- PSY77 I13 PRO2 BASED REMOTE MONITORING IN ULCERATIVE COLITIS: A PROSPECTIVE REAL WORLD STUDY**
Sebastian S¹, Roberts J², Waller J², Judge D³, Brown C⁴, Davies R⁴, **Kachroo S**⁵,¹Hull and East Yorkshire Hospitals, NHS Trust, Hull, UK, ²Adelphi Real World, Bollington, UK, ³Adelphi Real World, Manchester, UK, ⁴Merck Sharp & Dohme Ltd, Herfordshire, UK, ⁵Merck & Co., Inc., Kenilworth, NJ, USA
- PSY78 I14 ASSOCIATION BETWEEN BLEEDING EVENTS AND HEALTH-RELATED QUALITY-OF-LIFE IN ADULTS WITH SEVERE HEMOPHILIA A**
Watt M¹, Booth J², O'Hara J³, Jacob I³, Noone D³,¹Shire, Zug, Switzerland, ²Shire, Cambridge, MA, USA, ³HCD Economics, Cheshire, UK
- PSY79 I15 EFFECT OF PAINFUL LUMBOSACRAL RADICULOPATHY ON EMPLOYMENT AND QUALITY OF LIFE AMONG PATIENTS IN EUROPE**
Watson C¹, Vinikoor-Imler L¹, Gillespie A², Jackson J²,¹Biogen, Cambridge, MA, USA, ²Adelphi Real World, Bollington, Macclesfield, UK

SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies

- PSY80 I16 WITHDRAWN**
- PSY81 I17 DO US PAYERS CONSIDER COST-EFFECTIVENESS WHEN DEFINING PRESCRIPTION BENEFITS? A STUDY OF TARGETED THERAPIES FOR RHEUMATOID ARTHRITIS AND MODERATE-TO-SEVERE PSORIASIS**
Borga P¹, Pinedo-Martin G¹, Ribeiro A²,¹Lifescience Dynamics, London, UK, ²Lifescience Dynamics, Boston, MA, USA
- PSY82 I18 PRESCRIPTION DRUG COVERAGE FOR TREATMENT OF LOW BACK PAIN AMONG U.S. MEDICAID, MEDICARE ADVANTAGE AND COMMERCIAL INSURERS**
Lin DH¹, Jones CM², Compton W³, Heyward J¹, Losby J⁴, Murimi IB¹, Baldwin G⁴, Ballreich J⁵, Thomas D³, Bicket M⁶, Porter L⁷, Tierce J¹, Alexander GC¹,¹Johns Hopkins Bloomberg School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA, ²US Department of Health and Human Services, Washington, DC, USA, ³National Institutes of Health, National Institute on Drug Abuse, Rockville, MD, USA, ⁴Centers for Disease Control and Prevention, Atlanta, GA, USA, ⁵Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, USA, ⁶Johns Hopkins School of Medicine, Baltimore, MD, USA, ⁷National Institutes of Health, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
- PSY83 I19 COVERAGE OF NON-PHARMACOLOGIC TREATMENTS FOR LOWER BACK PAIN AMONG PUBLIC AND PRIVATE INSURERS IN THE UNITED STATES**
Heyward J¹, Jones CM², Compton W³, Lin DH¹, Losby J⁴, Murimi IB¹, Baldwin G⁴, Ballreich J⁵, Thomas D³, Bicket M⁶, Porter L⁷, Tierce J¹, Alexander GC¹,¹Johns Hopkins Bloomberg School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA, ²US Department of Health and Human Services, Washington, DC, USA, ³National Institutes of Health, National Institute on Drug Abuse, Rockville, MD, USA, ⁴Centers for Disease Control and Prevention, Atlanta, GA, USA, ⁵Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, USA, ⁶Johns Hopkins School of Medicine, Baltimore, MD, USA, ⁷National Institutes of Health, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
- PSY84 I20 A SYSTEMATIC REVIEW OF POPULATION-BASED STUDIES ON PAIN SELF-MANAGEMENT STRATEGIES AND OUTCOMES**
Axon DR, Patel M, Slack M, The University of Arizona, Tucson, AZ, USA
- PSY85 I21 DISEASE BURDEN AND INTEGRATED DISEASE MANAGEMENT OF BIOLOGIC TREATED PSORIASIS PATIENTS WITH PSORIATIC ARTHRITIS IN CLINICAL PRACTICE: RESULTS FROM MULTICOUNTRY STUDY IN EU5**
Karki C¹, Shah-Manek B², Lu Y¹, Collins P³, Triggs H³,¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, San Francisco, CA, USA, ³Ipsos Healthcare, London, UK
- PSY87 I22 DISEASE BURDEN AMONG PATIENTS WITH MULTIPLE SCLEROSIS NOT RECEIVING DISEASE MODIFYING TREATMENTS IN EUROPE AND THE UNITED STATES**
Shah-Manek B¹, Karki C², Brown H³, Hooper R³, White J³, Gabriele S³,¹Ipsos Healthcare, San Francisco, CA, USA, ²Ipsos Healthcare, New York, NY, USA, ³Ipsos Healthcare, London, UK

- PSY88 I23 SYSTEMATIC REVIEW OF DIAGNOSIS AND TREATMENT OF OBESITY AND BING- EATING SYNDROME**
Soto Molina H¹, Escobar Juárez Y¹, Perez-Martínez BA¹, del Valle C²,¹HS Estudios Farmacoeconómicos S.A. de C.V., Mexico City, Mexico, ²Productos MEDIX S.A de C.V., Ciudad de México, Mexico
- PSY89 I24 PAYER COVERAGE OF EXERCISE REGIMENS FOR TREATING LOWER BACK PAIN IN THE UNITED STATES: CURRENT LANDSCAPE AND OPPORTUNITIES TO ADDRESS THE BURDEN**
Spinner DS¹, Leverette MH¹, Green EB², Ringo MC³, Mihos MC¹, Browner BD⁴, Faulkner EC³,¹Evidera, Chapel Hill, NC, USA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³Evidera, Raleigh, NC, USA, ⁴Duke University School of Medicine, and Wake Forest University School of Medicine, Chapel Hill, NC, USA
- PSY90 J1 HEALTH RESOURCE BURDEN AMONG PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY: A RETROSPECTIVE CHART REVIEW STUDY**
Huynh L¹, Ivanova JI², Totev T¹, Bilginsoy M¹, Antin JH³, Roy A⁴, Bobbili PJ¹, Duh MS¹, Peffault de Latour R⁵,¹Analysis Group, Inc., Boston, MA, USA, ²Analysis Group, Inc., New York, MA, USA, ³Dana-Farber Cancer Institute, Boston, MA, USA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ⁵Hôpital Saint-Louis, Paris, France
- PSY91 J2 POOR MEDICATION ADHERENCE AND HIGH RATES OF TREATMENT DISCONTINUATION AMONG SCD PATIENTS TREATED WITH HYDROXYUREA**
Bhor M¹, Wang Y², Xie L², Halloway R¹, Arcona S³, Paulose J¹, Ogbomo A², Shen Y², Yuze H⁴, Shah N⁵,¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ²STATinMED Research, Ann Arbor, MI, USA, ³Novartis Pharmaceuticals, East Hanover, NJ, USA, ⁴New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, ⁵Duke University School of Medicine, Durham, NC, USA
- PSY92 J3 THE ANALYSIS OF MISSING DATA AROUND THE AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG) RECOMMENDATIONS FOR NEWBORN SCREENING (NBS) OF MAPLE SYRUP URINE DISEASE (MSUD)**
Daniels K, Rittenhouse B, MCPHS University, Boston, MA, USA
- PSY93 J4 EFFECT OF PATIENT INVOLVEMENT IN TREATMENT DECISION MAKING ON DISEASE OUTCOMES IN RHEUMATOID ARTHRITIS IN THE EU5**
Karki C¹, Panchal S¹, Baynton E², Shah-Manek B³,¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, London, UK, ³Ipsos Healthcare, San Francisco, CA, USA
- PSY94 J5 ORPHAN LEGISLATION - LEAVE NO ONE BEHIND?**
Wang GD, Macaulay R, PAREXEL International, London, UK
- PSY95 J6 IMPACT OF BIOSMILARS ON THE PRICE AND ACCESS OF ORIGINATORS IN MAJOR AUTOIMMUNE INDICATIONS: AN EU5 PERSPECTIVE**
Edathodu A, Mukku SR, Smith LA, Samuel JJ, Access Infinity, London, UK
- PSY96 J7 FDA ORPHAN EXPLOITATION? ARE PHARMA'S APPROACHES TO ORPHAN ONCOLOGY DRUG APPROVAL FUELLING A PUSH FOR REFORM BY THE FDA?**
Macaulay R, Cieply B, Wang GD, PAREXEL International, London, UK
- PSY97 J8 TRENDS IN APPROVAL OF ADVANCED THERAPY MEDICINAL PRODUCTS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION**
Alsheikh MY, Shukla V, Seoane-Vazquez E, Chapman University, Irvine, CA, USA
- PSY98 J9 PRESCRIPTION OPIOID USE BEFORE AND AFTER AN OVERDOSE EVENT IN MISSISSIPPI MEDICAID**
Inguva S¹, Gangan N¹, Pittman E¹, Banahan III B², Noble S³,¹Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, ²Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, MS, USA, ³Mississippi Division of Medicaid, Jackson, MS, USA
- PSY99 J10 DRUG SURVIVAL OF BIOLOGIC TREATMENTS FOR PSORIASIS PATIENTS: A REAL-WORLD STUDY IN SWEDEN**
 Yang F¹, Sharma A², Szilcz M¹, Freilich J¹, Anell B¹,¹PAREXEL International, Stockholm, Sweden, ²PAREXEL International, Chandigarh, India
- PSY100 J11 NONPERSISTENCE AND NONADHERENCE TO CHRONIC MEDICATIONS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION**

Zhou J¹, Han J¹, Nutescu EA¹, Patel P², Sweiss K¹, Calip GS¹,¹University of Illinois at Chicago, Chicago, IL, USA, ²Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA

PSY101 J12 COMPARISON OF ADHERENCE, PERSISTENCE, AND BLEED-RELATED EVENT RATES IN PATIENTS DIAGNOSED WITH IMMUNE THROMBOCYTOPENIA AND TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS

Stafkey-Mailey D¹, Lokhandwala T¹, Said Q², Bhor M², Graves A²,¹Xcenda, Palm Harbor, FL, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PSY102 J13 ACCOUNTING FOR DRUG WASTAGE IN HAEMATOLOGY-ONCOLOGY TREATMENTS: REVIEW OF CLINICAL PRACTICE AND RECENT TECHNOLOGY APPRAISALS IN ENGLAND

Wex J¹, **Mesana L**²,¹Amaris Consulting, London, UK, ²Amaris Consulting, Jersey City, NJ, USA

PSY103 J14 WITHDRAWN

PSY104 J15 IMPACT OF FLORIDA'S PRESCRIPTION DRUG MONITORING PROGRAM AND PILL MILL LAW ON HIGH-RISK PATIENTS— A COMPARATIVE INTERRUPTED TIME SERIES ANALYSIS

Chang H¹, Murimi IB², Faul M³, Rutkow L¹, **Alexander GC**²,¹Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, USA, ²Johns Hopkins Bloomberg School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA, ³Centers for Disease Control and Prevention, Atlanta, GA, USA

PSY105 J16 DESCRIPTIVE ANALYSIS OF COMMERCIALY INSURED ADULT OPIOID USERS IN THE UNITED STATES WITHOUT CANCER OR HOSPICE: 2007-2015

Calabrese MJ, Shaya FT,¹University of Maryland School of Pharmacy, Baltimore, MD, USA

PSY106 J17 EXPLORING COST SAVINGS OF A MODIFIED PLERIXAFOR PROTOCOL FOR USE IN AUTOLOGOUS STEM COLLECTION

Reese ES, Goto D, Sanikommu S, Lee C, Trivadi J, Farhangfar C, Copelan E, Avalos BR,¹Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA

PSY107 J18 TREATMENT WITH PROSTACYCLINS DELAYS AND REDUCES HOSPITAL READMISSIONS AMONG PAH PATIENTS

Noone JM¹, Blanchette CM¹, Howden R¹, Zacherle E¹, **Classi P**², Gordon K², Nelsen AC²,¹University of North Carolina at Charlotte, Charlotte, NC, USA, ²United Therapeutics, Durham, NC, USA

PSY108 J19 TREATMENT PATTERNS AND COSTS OF CARE IN COMMERCIALY-INSURED AND MEDICAID PATIENTS WITH TRANSFUSION-DEPENDENT SS-THALASSEMIA

Paramore C¹, Vlahiotis A², Moynihan M³, Cappell KA³, Ramirez-Santiago A¹,¹BlueBird Bio, Cambridge, MA, USA, ²IBM Watson Health, Cambridge, MA, USA, ³IBM Watson Health, Ann Arbor, MI, USA

PSY109 J20 MEDICAL RESOURCE UTILIZATION AND EXPENDITURES IN TEXAS MEDICAID PATIENTS TAKING DEFERASIROX DISPERSIBLE TABLETS AND THOSE TAKING DEFERASIROX FILM-COATED TABLETS

Richards K¹, Lawson KA¹, Said Q², Sasane R²,¹The University of Texas at Austin, Austin, TX, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PSY110 J21 REAL WORLD DATA ANALYSIS OF US CLAIMS DATABASE ON COAGULATION FACTOR IX EXPENDITURES IN PATIENTS WITH HEMOPHILIA B: STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE PRODUCTS

Spurden D¹, Chhabra A², Tortella BJ³, Fogarty PF³, Rubinstein E², Pleil A⁴, Alvir J²,¹Pfizer Limited, Surrey, UK, ²Pfizer Inc, New York, NY, USA, ³Pfizer Inc, Collegeville, PA, USA, ⁴Pfizer Inc, San Diego, CA, USA

PSY111 J22 HEALTHCARE UTILIZATION AND COST AMONG PATIENTS WITH HEREDITARY TRANSTHYRETIN (HATTR) AMYLOIDOSIS

Guthrie SD¹, Reddy SR², Tieu RS², Munday JS², Tarbox MH², Broder MS², Pollock MR³,¹Biopharma Strategic Consulting, LLC, San Francisco, CA, USA, ²Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, ³Reynolds Pollock & Associates, Sacramento, CA, USA

PSY112 J23 HEALTHCARE RESOURCE USE (HRU) ASSOCIATED WITH SEVERE ADVERSE EVENTS (AES) OF INTEREST IN ADULTS WITH RELAPSED OR REFRACTORY (R/R) B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN EU-4 COUNTRIES

Zhang X¹, Zhang L², Gijzen M², Cong Z¹,¹Amgen, Inc., Thousand Oaks, CA, USA, ²PRMA Consulting, Fleet, UK

PSY113 J24 TOTAL HEALTHCARE EXPENDITURES ASSOCIATED WITH BIOLOGICAL ANTI-RHEUMATIC DRUGS USE AMONG MEDICARE BENEFICIARIES WITH RHEUMATOID ARTHRITIS

- Gaitonde P**¹, Shaya F²,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland, Baltimore, MD, USA
- PSY114 K1** **AGE-RELATED HOSPITAL UTILIZATION AMONG PATIENTS WITH MARFAN SYNDROME**
Belk K¹, Mallow P², Craver CW¹,¹Vizient Inc., Mooresville, NC, USA, ²Xavier University, Cincinnati, OH, USA
- PSY115 K2** **PHARMACOECONOMIC EVALUATION OF OXYCODONE HYDROCHLORIDE PROLONGED-RELEASE TABLETS FOR MODERATE TO SEVERE CANCER PAIN TITRATION**
Zhou J, Jiang G, Wang Y, Chen K, Sichuan Cancer Hospital, Chengdu, China
- PSY116 K3** **COGNITIVE AND MIND-BODY THERAPIES FOR THE TREATMENT OF CHRONIC LOW BACK PAIN – A COST-EFFECTIVENESS ANALYSIS**
Kumar VM¹, Chapman RH¹, Rind D¹, Otuonye I¹, Webb M², Seidner M¹, Tice JA³,¹Institute for Clinical and Economic Review, Boston, MA, USA, ²Hebrew SeniorLife, Boston, MA, USA, ³UCSF School of Medicine, San Francisco, CA, USA
- PSY117 K4** **DO COMMERCIAL HEALTH CARE PRICES INFLUENCE MEDICARE SPENDING?**
Ning N, Trish E, Axeen S, Goldman DP, Romley JA, University of Southern California, Los Angeles, CA, USA
- PSY118 K5** **HEALTH CARE COSTS ASSOCIATED WITH DIFFERENT BIOLOGIC TREATMENT PATTERNS AMONG U.S. MEDICARE PATIENTS WITH PSORIASIS**
Li P¹, Glick HA², Puckett J¹, Jahnke J¹, Takeshita J¹, Gelfand JM¹, Li N³, Villacorta R⁴, McElligott S⁴, Doshi JA¹,¹University of Pennsylvania, Philadelphia, PA, USA, ²University of Pennsylvania, Philadelphia, NY, USA, ³Janssen Research & Development, LLC, Spring House, PA, USA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, USA
- PSY119 K6** **TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5**
Prada M¹, Berard I², Walzer S³, Darba J⁴, Greenwood B⁵,¹Intexo, Roma, Italy, ²NEXTEP, PARIS, France, ³MARs- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, ⁴Universitat de Barcelona, Barcelona, Spain, ⁵Decideum, London, W8 7JB, UK
- PSY120 K7** **ASSESSMENT OF COMMERCIAL AND MARKET ACCESS POTENTIAL AND CONSIDERATIONS FOR AN ULTRA-ORPHAN DRUG FOR RENAL DISEASE IN EU5**
Smith LA, Edathodu A, Samuel JJ, Mukku SR, Access Infinity, London, UK
- PSY122 K8** **SELF-REPORTED PAIN OUTCOMES OF PHARMACISTS WITH CHRONIC PAIN**
Axon DR¹, Bhattacharjee S², Warholak T¹, Slack M¹,¹The University of Arizona, Tucson, AZ, USA, ²University of Arizona, Tucson, AZ, USA
- PSY123 K9** **TYPES AND NUMBER OF STRATEGIES THAT PHARMACISTS USE TO MANAGE CHRONIC PAIN**
Axon DR¹, Bhattacharjee S², Warholak T¹, Slack M¹,¹The University of Arizona, Tucson, AZ, USA, ²University of Arizona, Tucson, AZ, USA
- PSY124 K10** **A PREDICTIVE MODEL TO IDENTIFY OPIOID-INDUCED RESPIRATORY DEPRESSION AMONG HOSPITALIZED PATIENTS**
Li Y, Brant JM, Billings Clinic, Billings, MT, USA
- PSY125 K11** **EPIDEMIOLOGY AND DISEASE BURDEN OF THREE DISEASES OF LYSOSOMAL DEPOSIT (EDLS) IN COLOMBIA: FABRY, GAUCHER AND HUNTER SYNDROME**
Taborda A¹, **Chavarriaga M**², Londoño D¹, Cindy C¹, Rodolfo D³, Suarez F⁴,¹Fundación Santa Fé de Bogotá, Bogotá, Colombia, ²Fundación Santa Fe de Bogota, Bogotá, Colombia, ³Fundación Cardioinfantil, Bogotá, Colombia, ⁴Pontificia universidad Javeriana, Bogotá, Colombia
- PSY126 K12** **TRENDS IN HTA SUBMISSIONS FOR RARE DISEASES: INSIGHTS FROM REVIEW OF NICE'S HIGHLY SPECIALIZED TECHNOLOGY (HST) ASSESSMENT REPORTS**
Aggarwal S¹, Topaloglu O¹, Kumar S²,¹NOVEL Health Strategies, Chevy Chase, MD, USA, ²Institute for Global Policy, Washington, DC, USA
- PSY127 K13** **PATIENT GROUP EXPERIENCES OF ENGAGEMENT IN HEALTH TECHNOLOGY APPRAISALS FOR RARE DISEASE TREATMENTS - A PILOT STUDY IN THE UK**
Nestler-Parr S¹, Upadhyaya S²,¹Rare Access, London, UK, ²National Institute for Health and Care Excellence (NICE), London, UK
- PSY129 K14** **OUTCOMES RELATED TO OPIOID PRESCRIBING AFTER ACADEMIC DETAILING: A REVIEW OF LITERATURE**

Zolekar A¹, White A², Fleming ML³, Thornton JD³, Wang Y¹,¹University of North Texas Health Science Center, Fort Worth, TX, USA, ²University of North Texas, Fort Worth, TX, USA, ³College of Pharmacy, University of Houston, Houston, TX, USA

PSY130 K15 PERCEPTIONS OF BIOSIMILARS ACROSS PHYSICIAN SPECIALITIES IN EUROPE

Shah-Manek B¹, Baskett A², Baynton E², Lu Y³, Karki C³,¹Ipsos Healthcare, San Francisco, CA, USA, ²Ipsos Healthcare, London, UK, ³Ipsos Healthcare, New York, NY, USA

PSY131 K16 RECENT REAL-WORLD TRENDS IN MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) BY US COMMUNITY RHEUMATOLOGISTS

Radtchenko J, Pallett P, Stockton CM, Feinberg BA, Cardinal Health, Dublin, OH, USA

PSY132 K17 PATTERNS OF USE OF DISEASE MODIFYING TREATMENTS AMONG PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN EUROPE BETWEEN 2012 AND 2016

Shah-Manek B¹, Karki C², Brown H³, Hooper R³, White J³, Gabriele S³,¹Ipsos Healthcare, San Francisco, CA, USA, ²Ipsos Healthcare, New York, NY, USA, ³Ipsos Healthcare, London, UK